DSS (DSS) 10-Q 18 Nov 21 2021 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2021	Oct. 20, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	001-32146
Entity Registrant Name	DSS, INC.
Entity Central Index Key	0000771999
Entity Tax Identification Number	16-1229730
Entity Incorporation, State or Country Code	NY
Entity Address, Address Line One	6 Framark Drive
Entity Address, City or Town	Victor
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	14564
City Area Code	(585)
Local Phone Number	325-3610
Title of 12(b) Security	Common Stock, $0.02 par value per share
Trading Symbol	DSS
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		79,745,886

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 69,137,000	$ 5,183,000
Restricted cash	350,000
Accounts receivable, net	2,774,000	3,589,000
Inventory	3,535,000	1,955,000
Assets held for sale - discontinued operations		531,000
Current portion of notes receivable	19,716,000
Prepaid expenses and other current assets	1,469,000	1,192,000
Total current assets	96,981,000	12,450,000
Property, plant and equipment, net	6,396,000	4,100,000
Investment in real estate, net	6,495,000
Other investments	11,337,000	1,788,000
Investment, equity method	16,107,000	12,234,000
Marketable securities	9,207,000	9,136,000
Notes receivable	4,483,000	537,000
Non-current assets held for sale - discontinued operations		790,000
Other assets	409,000	384,000
Right-of-use assets	198,000	182,000
Deferred tax asset, net	283,000
Goodwill	43,807,000	26,862,000
Other intangible assets, net	23,373,000	23,456,000
Total assets	219,076,000	91,919,000
Current liabilities:
Accounts payable	1,948,000	1,457,000
Accrued expenses and deferred revenue	9,555,000	5,260,000
Other current liabilities	415,000	1,435,000
Current liabilities held for sale - discontinued operations		275,000
Current portion of lease liability	122,000	167,000
Current portion of long-term debt, net	498,000	278,000
Total current liabilities	12,538,000	8,872,000
Long-term debt, net	6,664,000	1,976,000
Long term lease liability	75,000	15,000
Non-current liabilities held for sale - discontinued operations		505,000
Other long-term liabilities	507,000	507,000
Deferred tax liability, net		3,499,000
Commitments and contingencies (Note 9)
Stockholders’ equity
Preferred stock, $.02 par value; 47,000 shares authorized, shares issued and outstanding (43,000 on December 31, 2020); Liquidation value $1,000 per share, $- aggregate. $43,000,000 on December 31, 2020).		1,000
Common stock, $.02 par value; 200,000,000 shares authorized, 79,745,886 shares issued and outstanding (5,836,000 on December 31, 2020)	1,594,000	116,000
Additional paid-in capital	294,682,000	174,380,000
Non-controlling interest in subsidiary	23,395,000	3,430,000
Accumulated deficit	(120,379,000)	(101,382,000)
Total stockholders’ equity	199,292,000	76,545,000
Total liabilities and stockholders’ equity	$ 219,076,000	$ 91,919,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred Stock, No Par Value		$ 0.02
Preferred Stock, Shares Authorized		47,000
Preferred Stock, Shares Outstanding		43,000
Preferred Stock, Liquidation Preference Per Share		$ 1,000
Preferred Stock, Liquidation Preference, Value		$ 43,000,000
Common Stock, Par or Stated Value Per Share	$ 0.02	$ 0.02
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Shares, Issued	79,745,886	5,836,000
Common Stock, Shares, Outstanding	79,745,886	5,836,000

Consolidated Statements of Oper

Consolidated Statements of Operations Income (Loss) (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue:
Total revenue	$ 4,566,000	$ 3,686,000	$ 13,218,000	$ 10,202,000
Costs and expenses:
Cost of revenue, exclusive of depreciation and amortization	3,184,000	2,566,000	9,513,000	6,869,000
Selling, general and administrative (including stock-based compensation)	6,188,000	3,449,000	17,621,000	7,327,000
Depreciation and amortization	739,000	244,000	2,075,000	812,000
Total costs and expenses	10,111,000	6,259,000	29,209,000	15,008,000
Operating loss	(5,545,000)	(2,573,000)	(15,991,000)	(4,806,000)
Other income (expense):
Interest income	1,593,000	10,000	3,130,000	61,000
Other income	325,000		575,000
Interest expense	(31,000)	(29,000)	(157,000)	(102,000)
Gain on extinguishment of debt			116,000
(Loss) gain on investments	(2,996,000)	7,782,000	(10,894,000)	8,366,000
Loss on equity method investment	(1,645,000)		(2,556,000)
Amortization of deferred financing costs and debt discount		(8,000)		(8,000)
(Loss) income from continuing operations before income taxes	(8,299,000)	5,182,000	(25,777,000)	3,511,000
Income tax benefit	1,624,000		4,315,000
(Loss) income from continuing operations	(6,675,000)	5,182,000	(21,462,000)	3,511,000
Income (loss) from discontinued operations, net of tax		(240,000)	2,129,000	(1,442,000)
Net (loss) income	(6,675,000)	4,942,000	(19,333,000)	2,069,000
Loss from continuing operations attributed to noncontrolling interest	77,000	126,000	336,000	307,000
Net (loss) income attributable to common stockholders	$ (6,598,000)	$ 5,068,000	$ (18,997,000)	$ 2,376,000
(Loss) earnings per common share – continuing operations:
Basic	$ (0.09)	$ 1.16	$ (0.50)	$ 1.36
Diluted	(0.09)	0.68	(0.50)	0.98
(Loss) earnings per common share - discontinued operations:
Basic		(0.05)	0.05	(0.51)
Diluted		$ (0.03)	$ 0.05	$ (0.37)
Shares used in computing loss (earnings) per common share:
Basic	71,157,697	4,582,374	42,015,662	2,811,336
Diluted	71,157,697	7,805,629	42,015,662	3,893,597
Printed Products [Member]
Revenue:
Total revenue	$ 3,416,000	$ 2,971,000	$ 10,652,000	$ 8,409,000
Rental Income [Member]
Revenue:
Total revenue	184,000		184,000
Direct Marketing [Member]
Revenue:
Total revenue	$ 966,000	$ 715,000	$ 2,382,000	$ 1,793,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net (loss) income from continuing operations	$ (21,462,000)	$ 3,511,000
Adjustments to reconcile net (loss) income from continuing operations to net cash used by operating activities:
Depreciation and amortization	2,075,000	812,000
Stock based compensation	74,000	181,000
Loss on equity method investment	2,556,000
Loss (gain) on investments	10,894,000	(8,365,000)
Gain on extinguishment of debt	(116,000)
Deferred tax benefit	(4,315,000)
Accretion of debt discount, origination fee and prepaid interest	(2,287,000)
Decrease (increase) in assets:
Accounts receivable	829,000	716,000
Inventory	(1,580,000)	(1,147,000)
Prepaid expenses and other current assets	(277,000)	(678,000)
Other assets	(25,000)	1,321,000
Increase (decrease) in liabilities:
Accounts payable	432,000	(99,000)
Accrued expenses	1,808,000	43,000
Other liabilities	(1,054,000)	859,000
Net cash used by operating activities	(12,448,000)	(2,846,000)
Cash flows from investing activities:
Purchase of property, plant and equipment	(2,816,000)	(99,000)
Purchase of real estate	(6,565,000)
Purchase of investment	(19,026,000)	(100,000)
Purchase of marketable securities	(8,789,000)	(6,581,000)
Acquisition of American Pacific Bancorp, Inc.	1,235,000
Purchase of equity investment	(1,276,000)
Sale of marketable securities	9,185,000
Note receivable investment	(24,048,000)	(574,000)
Purchase of intangible assets	(1,115,000)	111,000
Net cash used by investing activities	(53,215,000)	(7,243,000)
Cash flows from financing activities:
Payments of long-term debt	(1,893,000)	(144,000)
Borrowings of long-term debt	7,102,000	1,272,000
Payments of revolving lines of credit, net		(500,000)
Deferred financing fees	(186,000)
Issuances of common stock, net of issuance costs	121,737,000	20,149,000
Net cash provided by financing activities	126,760,000	20,777,000
Cash flows from discontinued operations:
Cash provided (used) by discontinued operations	207,000	(438,000)
Cash provided by investing activities	3,000,000	876,000
Cash used by financing activities		(577,000)
Net cash provided (used) by discontinued operations	3,207,000	(139,000)
Net increase in cash	64,304,000	10,549,000
Cash, cash equivalents, and restricted cash at beginning of period	5,183,000	1,096,000
Cash, cash equivalents, and restricted cash at end of period	$ 69,487,000	$ 11,645,000

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-in Capital [Member]	Noncontrolling Interest [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 24,000		$ 115,560,000		$ (103,281,000)	$ 12,303,000
Beginning balance, shares at Dec. 31, 2019	1,206,000
Issuance of common stock, net	$ 18,000		4,036,000			4,054,000
Beginning balance, shares	863,000
Stock based payments, net of tax effect			28,000			28,000
Beginning balance, shares
Net (loss) income				(67,000)	(1,900,000)	(1,967,000)
Stock based payments, net of tax effect			(28,000)			(28,000)
Ending balance, value at Mar. 31, 2020	$ 42,000		119,624,000	(67,000)	(105,181,000)	14,418,000
Beginning balance, shares at Mar. 31, 2020	2,069,000
Beginning balance, value at Dec. 31, 2019	$ 24,000		115,560,000		(103,281,000)	12,303,000
Beginning balance, shares at Dec. 31, 2019	1,206,000
Net (loss) income						2,069,000
Ending balance, value at Sep. 30, 2020	$ 103,000	$ 1,000	174,423,000	(307,000)	(100,905,000)	73,315,000
Beginning balance, shares at Sep. 30, 2020	5,174,000	47,000
Beginning balance, value at Mar. 31, 2020	$ 42,000		119,624,000	(67,000)	(105,181,000)	14,418,000
Beginning balance, shares at Mar. 31, 2020	2,069,000
Issuance of common stock, net	$ 17,000		6,168,000			6,185,000
Beginning balance, shares	896,000
Stock based payments, net of tax effect	$ 1,000		266,000			267,000
Beginning balance, shares	30,000
Net (loss) income				(114,000)	(792,000)	(906,000)
Stock based payments, net of tax effect	(1,000)		(266,000)			(267,000)
Ending balance, value at Jun. 30, 2020	$ 60,000		126,058,000	(181,000)	(105,973,000)	19,964,000
Beginning balance, shares at Jun. 30, 2020	2,995,000
Issuance of common stock, net	$ 43,000		13,045,000			13,088,000
Beginning balance, shares	2,159,000
Stock based payments, net of tax effect			133,000			133,000
Beginning balance, shares	20,000
Issuance of preferred stock, net		$ 1,000	35,187,000			35,188,000
Beginning balance, shares		47,000
Net (loss) income				(126,000)	5,068,000	4,942,000
Stock based payments, net of tax effect			(133,000)			(133,000)
Ending balance, value at Sep. 30, 2020	$ 103,000	$ 1,000	174,423,000	(307,000)	(100,905,000)	73,315,000
Beginning balance, shares at Sep. 30, 2020	5,174,000	47,000
Beginning balance, value at Dec. 31, 2020	$ 116,000	$ 1,000	174,380,000	3,430,000	(101,382,000)	76,545,000
Beginning balance, shares at Dec. 31, 2020	5,836,000	43,000
Issuance of common stock, net	$ 436,000		60,632,000			61,068,000
Beginning balance, shares	21,834,000
Stock based payments, net of tax effect			15,000			15,000
Beginning balance, shares
Conversion of preferred stock
Net (loss) income				(31,000)	(3,981,000)	(4,012,000)
Stock based payments, net of tax effect			(15,000)			(15,000)
Ending balance, value at Mar. 31, 2021	$ 552,000	$ 1,000	235,027,000	3,399,000	(105,363,000)	133,616,000
Beginning balance, shares at Mar. 31, 2021	27,670,000	43,000
Beginning balance, value at Dec. 31, 2020	$ 116,000	$ 1,000	174,380,000	3,430,000	(101,382,000)	76,545,000
Beginning balance, shares at Dec. 31, 2020	5,836,000	43,000
Net (loss) income						(19,333,000)
Ending balance, value at Sep. 30, 2021	$ 1,594,000		294,682,000	23,395,000	(120,379,000)	199,292,000
Beginning balance, shares at Sep. 30, 2021	79,746,000
Beginning balance, value at Mar. 31, 2021	$ 552,000	$ 1,000	235,027,000	3,399,000	(105,363,000)	133,616,000
Beginning balance, shares at Mar. 31, 2021	27,670,000	43,000
Issuance of common stock, net	$ 668,000		45,080,000			45,748,000
Beginning balance, shares	33,350,000
Stock based payments, net of tax effect			30,000			30,000
Beginning balance, shares
Conversion of preferred stock	$ 131,000	$ (1,000)	(130,000)
Beginning balance, shares	6,570,000	(43,000)
Net (loss) income				(228,000)	(8,418,000)	(8,646,000)
Stock based payments, net of tax effect			(30,000)			(30,000)
Ending balance, value at Jun. 30, 2021	$ 1,351,000		279,947,000	3,171,000	(113,781,000)	170,688,000
Beginning balance, shares at Jun. 30, 2021	67,590,000
Issuance of common stock, net	$ 243,000		14,722,000			14,965,000
Beginning balance, shares	12,156,000
Stock based payments, net of tax effect			13,000			13,000
Acquisition of American Pacific Bancorp				20,301,000		20,301,000
Acquisition of American Pacific Bancorp
Net (loss) income				(77,000)	(6,598,000)	(6,675,000)
Stock based payments, net of tax effect			(13,000)			(13,000)
Ending balance, value at Sep. 30, 2021	$ 1,594,000		$ 294,682,000	$ 23,395,000	$ (120,379,000)	$ 199,292,000
Beginning balance, shares at Sep. 30, 2021	79,746,000

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Significant Accounting Policies	1. Basis of Presentation and Significant Accounting Policies The Company, incorporated in the state of New York in May 1984 has conducted business in the name of Document Security Systems, Inc. On September 16, 2021, the board of directors approved an agreement and plan of merger with a wholly-owned subsidiary, DSS, Inc. (a New York corporation, incorporated in August 2020), for the sole purpose of effecting a name change from Document Security Systems, Inc. to DSS, Inc. This change became effective on September 30, 2021. DSS, Inc. maintained the same trading symbol “DSS” and updated its CUSIP number to 26253C 102. DSS, Inc. (together with its consolidated subsidiaries, referred to herein as “DSS,” “we,” “us,” “our” or the “Company”) currently operates nine (9) distinct business lines with operations and locations around the globe. These business lines are: (1) Premier Packaging, (2) IP Monetization, (3) Direct Marketing/Online Sales Group, (4) Blockchain Technology, (5) Securities and Fintech Group, (6) BioHealth Group, (7) Secure Living, (8) Energy Group, and (9) Investment Banking. Each of these business lines are in different stages of development, growth, and income generation. Of the nine business lines, two of the those have historically been the led by core subsidiaries of the Company: (1) Premier Packaging Corporation (“Premier Packaging”), and (2) DSS Technology Management, Inc. (“IP Monetization”). Premier Packaging operates in the paper board folding carton, smart packaging, and document security printing markets. It markets, manufactures, and sells sophisticated custom folding cartons, mailers, photo sleeves, and complex 3-dimensional direct mail solutions designed to provide functionality, marketability, and sustainability to product packaging while providing counterfeit protection and consumer engagement platform. DSS Technology Management Inc., manages, licenses, and acquires intellectual property assets for the purpose of monetizing these assets through a variety of value-enhancing initiatives, including, but not limited to, investments in the development and commercialization of patented technologies, licensing, strategic partnerships, and commercial litigation. The activities surrounding our IP Technology Management segment have significantly decreased. In 2020, under its (3) Decentralize Sharing Systems, Inc. (“Decentralized”) subsidiary, the Company created a third business segment, Direct Marketing/Online Sales Group (“Direct”). This group provides services to assist companies in the growing gig economic business model of peer-to-peer direct marketing. Direct specializes in marketing and distributing its products and services through its subsidiaries, partner networks, and online marketplaces. Products include health and wellness for personal care, healthy living and lifestyle, and travel. Direct will also help to support the direct selling industry by offering services to its piers that streamline operations, enhance financing, and provide back-end business continuity. In addition to the three business lines and subsidiaries listed above, in 2020 and 2021, DSS has created four new business lines, and wholly owned subsidiaries. (4) Blockchain Technology, led by DSS Blockchain Security, Inc (“DSS Blockchain”)., a Nevada corporation, specializes in the development of blockchain security technologies for tracking and tracing solutions for supply chain logistics and cyber securities across global markets. (5) Securities and Fintech, led by DSS Securities, Inc. (“DSS Securities”), a Nevada corporation, was established to develop and/or acquire assets and investments in the securities trading and/or funds management arena. Further, Securities, in partnership with recognized global leaders in alternative trading systems, intends to own and operate in the US a single or multiple vertical digital asset exchanges for securities, tokenized assets, utility tokens, stable coins and cryptocurrency via a digital asset trading platform using blockchain technology. The scope of services within this section is planned to include asset issuance and allocation (securities and cryptocurrency), FPO, IPO, ITO, PPO, STO and UTO listings on a primary market(s), asset digitization/tokenization (securities, currency and cryptocurrency), and the listing and trading of digital assets (securities and cryptocurrency) on a secondary market(s). Also in this segment is the Company’s real estate investment trust (“REIT”), organized for the purposes of acquiring hospitals and other acute or post-acute care centers from leading clinical operators with dominant market share in secondary and tertiary markets, and leasing each property to a single operator under a triple-net lease. the REIT was formed to originate, acquire, and lease a credit-centric portfolio of licensed medical real estate. (6) BioHealth Group, led by DSS BioHealth Security, Inc. (“DSS BioHealth”), a Nevada corporation, is our business line which we will intend to invest in or to acquire companies related to the bio-health and biomedical field, including businesses focused on the research to advance drug discovery and development for the prevention, inhibition, and treatment of neurological, oncology and immuno-related diseases. This new division will place special focus on open-air defense initiatives, which curb transmission of air-borne infectious diseases such as tuberculosis and influenza, among others. (7) Secure Living, led by DSS Secure Living, Inc. (“DSS Secure Living”), a Nevada Corporation, will develop top of the line advanced technology, energy efficiency, quality of life living environments and home security for everyone for new construction and renovations of residential single and multifamily living facilities. The activity in DSS Blockchain and DSS Secure Living has been minimal or in various start-up or organizational phases. (8) Energy Group, organized under the Company’s subsidiary Alset Energy, Inc., a Texas corporation, has been established to help lead the Company’s clean energy future with a focus on environmental responsibility and sustainability measures. (9) Investment Banking, created in September 2021 as part of the Company’s acquisition of American Pacific Bancorp. Inc., a Texas corporation, is organized for the purposes of being a financial network holding company, focused on providing commercial loans and acquiring equity positions in (i) undervalued commercial bank(s), bank holding companies and nonbanking licensed financial companies operating in the United States, South East Asia, Taiwan, Japan and South Korea, and (ii) companies engaged in—nonbanking activities closely related to banking, including loan syndication services, mortgage banking, trust and escrow services, banking technology, loan servicing, equipment leasing, problem asset management, SPAC (special purpose acquisition company) consulting, and advisory capital raising services. From this financial platform, the Company shall provide an integrated suite of financial services for businesses that shall include commercial business lines of credit, land development financing, inventory financing, third party loan servicing, and services that address the financial needs of the world Gig Economy. On August 21, 2020, the Company, completed its acquisition of Impact BioMedical, Inc. (“Impact BioMedical”), pursuant to a Share Exchange Agreement by and among the Company, DSS BioHealth Security, Inc. (“DSS BioHealth”), Alset International Limited (formally Singapore eDevelopment Ltd.), and Global Biomedical Pte Ltd. (“GBM”), which was previously approved by the Company’s shareholders (the “Share Exchange”). Under the terms of the Share Exchange, the Company issued 483,334 0.02 6.48 46,868 Impact BioMedical strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades. By tapping into the scientific expertise of its partners, Impact BioMedical has undertook a concerted effort in the research and development (R&D), drug discovery and development for the prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. On September 9, 2021, the Company finalized a stock purchase agreement (the “SPA”) with American Pacific Bancorp, Inc. (“APB”), which provided for an investment of $ 40,000,200 by the Company into APB for an aggregate of 6,666,700 shares of the APB’s Class A Common Stock, par value $ 0.01 per share. Subject to the terms and conditions contained in the SPA, the shares issued at a purchase price of $ 6.00 per share. As a result of this transaction, DSS became the majority owner of APB. (see Note 5). On September 13, 2021, the Company finalized a shareholder agreement and joint venture between its subsidiary, DSS Financial Management, Inc. (“DFMI”) and HR1 Holdings Limited (“HR1”), a company incorporated in the British Virgin Islands, for the purpose to operate a vehicle for private and institutional investors seeking a highly liquid investment fund with attractive risk adjusted returns relative to market unpredictability and volatility. Under the terms of this agreement, 4000 shares or 40% of the Company’s subsidiary Liquid Asset Limited Management Limited (“LVAM”), a Hong Kong company was transferred to HR1 whereas at the conclusion of the transaction DFMI would own 60% of LVAM and HR1 would own 40%. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 8.03 of Regulation S-X for smaller reporting companies. Accordingly, these statements do not include all the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying balance sheets and related interim statements of operations and cash flows include all adjustments considered necessary for their fair presentation in accordance with U.S. GAAP. All significant intercompany transactions have been eliminated in consolidation. Interim results are not necessarily indicative of results expected for the full year. For further information regarding the Company’s accounting policies, refer to the audited consolidated financial statements and footnotes thereto included in the Company’s Form 10-K for the fiscal year ended December 31, 2020. Principles of Consolidation Use of Estimates Reclassifications - Certain amounts on the accompanying consolidated balance sheets for the year ended December 31, 2020, have been reclassified to conform to current period presentation. Restricted cash Notes receivable, unearned interest, and related recognition The Company records all future payments of principal and interest on notes as notes receivable, which are then offset by the amount of any related unearned interest income. For financial statement purposes, the Company reports the net investment in the notes receivable on the consolidated balance sheet as current or long-term based on the maturity date of the underlying notes. Such net investment is comprised of the amount advanced on the loans, adjusting for net deferred loan fees or costs incurred at origination, amounts allocated to warrants received upon origination, and any payments received in advance. The unearned interest is recognized over the term of the notes and the income portion of each note payment is calculated so as to generate a constant rate of return on the net balance outstanding. Net deferred loan fees or costs, together with discounts recognized in connection with warrants acquired at origination, are accreted as an adjustment to yield over the term of the loan. Investments For equity method investments, the Company regularly reviews its investments to determine whether there is a decline in fair value below book value. If there is a decline that is other-than-temporary, the investment is written down to fair value. See Note 6 for further discussion on investments. Fair Value of Financial Instruments - ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets. ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts reported in the balance sheet of cash and cash equivalents, accounts receivable, prepaids, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. Marketable securities classify as a Level 1 fair value financial instrument. The fair value of notes receivable approximates their carrying value as the stated or discounted rates of the notes do reflect recent market conditions. The fair value of revolving credit lines notes payable and long-term debt approximates their carrying value as the stated or discounted rates of the debt reflect recent market conditions. The fair value of investments where the fair value is not considered readily determinable, are carried at cost. Impairment of Long-Lived Assets and Goodwill Related Party Liabilities – On April 1, 2020 the Company’s HWH World, Inc subsidiary has a service agreement with HWH Korea, a subsidiary of Alset International Limited (“Alset Intl.”) (formally Singapore eDevelopment Limited). The Chairman of the Company, Mr. Heng Fai Ambrose Chan, is the Executive Director and Chief Executive Officer of Alset Intl. Mr. Chan is also the majority shareholder of Alset Intl as well as the largest shareholder of the Company. The Company also owns approximately 127,179,000 shares of Alset Intl, a company publicly listed on the Singapore Exchange Limited. This service agreement will allow HWH Korea to utilize the Company’s merchant account in connection with their direct marketing network with periodic remittance of the cash collected to them for a fee of 2.5 % of amounts collected. As of September 30, 2021, the Company had collected approximately $ 0 as compared to $ 1,100,000 as of December 31, 2020, on behalf of HWH Korea, which is included in Accrued expenses and deferred revenue on the consolidated balance sheet. There were no amounts outstanding to this related party at September 30, 2021. Acquisitions Business combinations and non-controlling interests are recorded in accordance with FASB ASC 805 Business Combinations. Under the guidance, the assets and liabilities of the acquired business are recorded at their fair values at the date of acquisition and all acquisition costs are expensed as incurred. The excess of the purchase price over the estimated fair values is recorded as goodwill. If the fair value of the assets acquired exceeds the purchase price and the liabilities assumed, then a gain on acquisition is recorded. The application of business combination accounting requires the use of significant estimates and assumptions. Acquisition of assets are recorded at their relative fair value based on total accumulated costs of the acquisition. Direct acquisition-related costs are capitalized as a component of the acquired assets. This includes all costs related to finding, analyzing and negotiating a transaction. The allocation of the purchase price is an area that requires judgment and significant estimates. Tangible and intangible assets include land, building and improvements, furniture, fixtures and equipment, acquired above market and below market leases, in-place lease value (if applicable). Acquisition-date fair values of assets and assumed liabilities are determined based on replacement costs, appraised values, and estimated fair values using methods similar to those used by independent appraisers and that use appropriate discount and/or capitalization rates and available market information. Discontinued Operations On May 7, 2021, the Company completed the sale of 100 (Loss) Earnings Per Common Share - The Company presents basic and diluted (loss) earnings per share. Basic (loss) earnings per share reflect the actual weighted average of shares issued and outstanding during the period. Diluted (loss) earnings per share are computed including the number of additional shares from outstanding warrants, stock options and preferred stock that would have been outstanding if dilutive potential shares had been issued and is calculated utilizing the treasury stock method. In a loss period, the calculation for basic and diluted (loss) earnings per share is the same, as the impact of potential common shares is anti-dilutive. Concentration of Credit Risk - During the nine months ended September 30, 2021, two customers accounted for 43 % of our consolidated revenue. As of September 30, 2021, these two customers accounted for 73 % of our consolidated trade accounts receivable balance. During the nine-months ended September 30, 2020, these two customers accounted for 37 % of our consolidated revenue and 48 % of our consolidated trade accounts receivable balance. Income Taxes Recent Accounting Pronouncements Impact of COVID-19 Outbreak

Revenue

Revenue	9 Months Ended
	Sep. 30, 2021
Revenue from Contract with Customer [Abstract]
Revenue	2. Revenue The Company recognizes its products and services revenue based on when the title passes to the customer or when the service is completed and accepted by the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for shipped product or service provided. Sales and other taxes billed and collected from customers are excluded from revenue. The Company recognizes rental income associated with its REIT, including rental abatements and contractual fixed increases attributable to operating leases, where collection has been considered probable, on a straight-line basis over the term of the related lease. The Company generates revenue from its direct marketing line of business primarily through internet sales and recognizes revenue as items are shipped. As of September 30, 2021, the Company had no unsatisfied performance obligations for contracts with an original expected duration of greater than one year. Pursuant to Topic 606, the Company has applied the practical expedient with respect to disclosure of the deferral and future expected timing of revenue recognition for transaction price allocated to remaining performance obligations. The Company elected the practical expedient allowing it to not recognize as a contract asset the commission paid to its salesforce on the sale of its products as an incremental cost of obtaining a contract with a customer but rather recognize such commission as expense when incurred as the amortization period of the asset that the Company would have otherwise recognized is one year or less. Accounts Receivable The Company extends credit to its customers in the normal course of business. The Company performs ongoing credit evaluations and generally does not require collateral. Payment terms are generally 30 days but up to net 105 for certain customers. The Company carries its trade accounts receivable at invoice amount less an allowance for doubtful accounts. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance for doubtful accounts based upon management’s estimates that include a review of the history of past write-offs and collections and an analysis of current credit conditions. At September 30, 2021, the Company established a reserve for doubtful accounts of approximately $ 84,000 25,000 Sales Commissions Sales commissions are expensed as incurred for contracts with an expected duration of one year or less. There were no sales commissions capitalized as of September 30, 2021. Shipping and Handling Costs Costs incurred by the Company related to shipping and handling are included in cost of products sold. Amounts charged to customers pertaining to these costs are reflected as revenue. See Note 14 for disaggregated revenue information.

Notes Receivable

Notes Receivable	9 Months Ended
	Sep. 30, 2021
Receivables [Abstract]
Notes Receivable	3. Notes Receivable Century TBD Holdings, LLC On October 10, 2019, the Company entered into a convertible promissory note (“TBD Note”) with Century TBD Holdings, LLC (“TBD”), a Florida limited liability company. The Company loaned the principal sum of $ 500,000 , of which up to $ 500,000 and all accrued interest can be paid by an “Optional Conversion” of such amount up to 19.8 % (non-dilutable) of all outstanding membership interest in TBD. This TBD Note accrues interest at 6 % and matures on October 9, 2021 . As of September 30, 2021, and December 31, 2020, this TBD Note had outstanding principal and interest of approximately $ 537,000. This asset was classified as Current portion of notes receivable on the consolidated balance sheet as September 30, 2021, and as Notes receivable on the consolidated balance sheet as of December 31, 2020. On December 30, 2020, the Company signed a binding letter of intent with West Park Capital, Inc (“West Park”) and TBD where the parties agreed to prepare a note and stock exchange agreement whereby DSS will assign the TBD Note to West Park and West Park shall issue to DSS a stock certificate reflecting 7.5 % of the issued and outstanding shares of West Park. This note and stock exchange agreement is expected to be finalized sometime during the fourth quarter of 2021. GSX Group Limited On February 8, 2021, the Company entered into a convertible promissory note (“GSX Note”) with GSX Group Limited (“GSX”), a company registered in Gibraltar. The Company loaned the principal sum of $ 800,000 , with principal and interest at a rate of 4 %, due in one year from date of issuance. The outstanding principal and interest as of September 30, 2021, approximated $ 821,000 , and is classified as a Current Asset on the Consolidated Balance Sheets at September 30, 2021. The GSX Note shall be converted, at the Company’s option, into shares of GSX at the conversion price of $ 1.05 per share. On February 3, 2021, USX Holdings Company, Inc., a subsidiary of the Company entered into a binding joint venture term sheet (“GSX JV”) for the creation of a USA based joint venture alternative trading system or exchange (“JV Exchange”). During the nine-months ended September 30, 2021, the Company and GSX finalized the terms of the JV Exchange. Dustin Crum On February 21, 2021, Impact BioMedical, Inc. a subsidiary of the Company, entered into a promissory note (“Crum Note”) with Dustin Crum (“ Mr. Crum”). The Company loaned the principal sum of $ 206,000 , with interest at a rate of 6.5 %, and maturity date of August 19, 2022 . Monthly payments are due on the twenty-first day of each month and continuing each month thereafter until August 19, 2022, at which time all accrued interest and the entire remaining principal shall be due and payable in full. This note is secured by certain real property situated in Collier County, Florida. The outstanding principal and interest as of September 30, 2021, approximated $ 197,000 and is classified in current notes receivable on the accompanying consolidated balance sheets. Sharing Services Global Corporation On April 5, 2021, Decentralized Sharing Systems, Inc., a subsidiary of the Company entered into a convertible promissory note (“SHRG Note”) with Sharing Services Global Corporation (“SHRG”), a company registered in the state of Nevada. The Company loaned the principal sum of $ 30,000,000 8 April 5, 2024 0.20 3,000,000 83,000 27,000,000 15,000,000 12,000,000 150,000,000 0.22 15,043,000 16,830,000 The Company, via three (3) of the Company’s existing board members, currently holds three (3) of the five (5) SHRG board of director seats. Mr. John “JT” Thatch, DSS’s Lead Independent Director and as well the CEO of SHRG is on the SHRG Board, along with Mr. Chan, DSS’s Executive Chairman of the board of directors (joined the SHRG Board effective May 4, 2020), and Mr. Frank D. Heuszel, the CEO of the Company (joined the SHRG Board effective September 29, 2020). Sentinel Brokers Company, Inc. On May 13, 2021, a subsidiary of the Company entered a revolving credit promissory note (“Sentinel Note”) with Sentinel Brokers Company, Inc. (“Sentinel”), a company registered in the state of New York. The Sentinel Note has an aggregate principal balance up to $ 600,000 , to be funded at request of Sentinel. The Sentinel Note, which incurs interest at a rate of 6.65 % is payable in areas until the principal is paid in full at the maturity date of May 13, 2023 . As of September 30, 2021, there is $ 0 outstanding on the Sentinel Note. Also on May 13, 2021, the Company entered into a stock purchase agreement (“Sentinel Agreement”) to acquire a 24.9 % equity position of Sentinel for the purchase price of $ 300,000 . See Note 6. Puradigm, LLC On May 14, 2021 5,000,000 6.5 May 14, 2023 18 4,156,000 400,000 Harris-Montgomery Counties Management District On September 23, 2021, APB entered into refunding bond anticipatory note (“District Note”) with Harris-Montgomery Counties Management District (the “District”), which operates as a conservation and reclamation district pursuant to Chapter 3891, Texas Special District Local Laws Code; Chapter 375, Texas Local Government Code; and Chapter 49, Texas Water Code. The District Note was in the sum of $ 3,500,000 and incurs interest at a rate of 4.15% per annum. Principal and interest are due in full on September 22, 2022 . This note may be redeemed prior to maturity with 10 days written notice to APB at a price equal to principal plus interest accrued on the redemption date. The District Note is included in current portion of notes receivable on the consolidated balance sheet at September 30, 2021.

Financial Instruments

Financial Instruments	9 Months Ended
	Sep. 30, 2021
Investments, All Other Investments [Abstract]
Financial Instruments	4. Financial Instruments Cash, Cash Equivalents, Restricted Cash and Marketable Securities The following tables show the Company’s cash, cash equivalents, restricted cash, and marketable securities by significant investment category as of September 30, 2021, and December 31, 2020: Schedule of Cash and Marketable Securities by Significant Investment Category 2021 Adjusted Cost Unrealized Gain/(Loss) Fair Value Cash, Cash Equivalents, and Restricted Cash Marketable Securities Investments Cash and cash equivalents $ 51,438,000 $ - $ 51,438,000 $ 51,438,000 $ - $ - Restricted cash 350,000 - 350,000 350,000 - - Level 1 Money Market Funds 17,699,000 - 17,699,000 17,699,000 - - Marketable Securities 6,608,000 2,599,000 9,207,000 - 9,207,000 - Level 2 Warrants 15,657,000 (9,121,000 ) 6,536,000 - - 6,536,000 Total $ 91,752,000 $ (6,522,000 ) $ 85,230,000 $ 69,487,000 $ 9,207,000 $ 6,536,000 2020 Adjusted Cost Unrealized Gain/(Loss) Fair Value Cash and Cash Equivalents Marketable Securities Investment Cash and cash equivalents $ 1,690,000 $ - $ 1,690,000 $ 1,690,000 $ - $ - Level 1 Money Market Funds 3,493,000 - 3,493,000 3,493,000 - - Marketable Securities 5,641,000 3,495,000 9,136,000 - 9,136,000 - Level 2 Warrants 700,000 356,000 1,056,000 - - 1,056,000 Total $ 11,524,000 $ 3,851,000 $ 15,375,000 $ 5,183,000 $ 9,136,000 $ 1,056,000 The Company typically invests in highly rated securities, with the primary objective of minimizing the potential risk of principal loss. The Company’s investment policy generally requires securities to be investment grade and limits the amount of credit exposure to any one issuer. Fair values were determined for each individual security in the investment portfolio.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Acquisitions	5. Acquisitions American Medical REIT Inc. On March 3, 2020, the Company, via its subsidiary DSS Securities, entered into a share subscription agreement and loan arrangement with LiquidValue Asset Management Pte Ltd., AMRE Asset Management, Inc. and American Medical REIT Inc. under which it acquired a 52.5 93 Effective on March 3, 2020, the Company entered into a Promissory Note with AMRE, pursuant to which AMRE has issued the Company a promissory note for the principal amount of $ 800,000 (the “Note”). The Note matures on March 3, 2022 and accrues interest at the rate of 8.0 % per annum and shall be payable in accordance with the terms set forth in the Note. Under the Note, AMRE may prepay or repay all or any portion of the Note at any time, without a premium or penalty. If not sooner prepaid, the entire unpaid principal balance of the Note including accrued interest will be due and payable in full on March 3, 2022. The Note also provides the Company an option to provide AMRE an additional $ 800,000 on the same terms and conditions as the Note, including the issuance of warrants as described below. As further incentive to enter into the Note, AMRE issued the Company warrants to purchase 160,000 shares of AMRE common stock (the “Warrants”). The Warrants have an exercise price of $ 5.00 per share, subject to adjustment as set forth in the Warrants, and expire on March 3, 2024 . Pursuant to the Warrants, if AMRE files a registration statement with the Securities and Exchange Commission for an initial public offering (“IPO”) of AMRE’s common stock and the IPO price per share offered to the public is less than $ 10.00 per share, the exercise price of the Warrants shall be adjusted downward to 50 % of the IPO price. The Warrants also grants piggyback registration rights to the Company as set forth in the Warrants. As of September 30, 2021, this Note had outstanding principal and interest of approximately $ 898,000 . Upon consolidation this Note is eliminated. AMRE entered into a $ 200,000 unsecured promissory note with LiquidValue Asset Management Pte Ltd (“LVAMPTE”). The Note calls for interest to be paid annually on March 2 with interest fixed at 8.0 %. See Note 7 for further details. LVAMPTE is majority owned subsidiary of Alset International Limited whose Chief Executive Office and largest shareholder is Heng Fai Ambrose Chan, the Chairman of the Board and largest shareholder of the Company. On June 18, 2021, DSS Securities, entered into a stock purchase agreement with AMRE to acquire 264,525 10 2,645,250 264,525 93 On June 18, 2021, AMRE Shelton, LLC., (“AMRE Shelton”) a subsidiary of AMRE financed the purchase of a 40,000 square foot, 2.0 story, Class A+ multi-tenant medical office building located on a 13.62-acre site in Shelton, Connecticut (See Note 7) for the purchase price of $ 7,150,000 ubstantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. 4,640,000 1,600,000 325,000 585,000 3 1,500,000 During the three- and nine-months ended September 30, 2021, AMRE had net losses of $ 545,000 778,000 38,000 131,000 Impact BioMedical, Inc. On August 21, 2020, the Company, completed its acquisition of Impact BioMedical, Inc. (“Impact”), pursuant to a Share Exchange Agreement by and among the Company, DSS BioHealth, and related parties Alset Intl (formally Singapore eDevelopment Limited), and Global Biomedical Pte Ltd. (“GBM”) which was previously approved by the Company’s shareholders (the “Share Exchange”).Under the terms of the Share Exchange, the Company issued 483,334 shares of the Company’s common stock, par value $ 0.02 per share, nominally valued at $ 6.48 per share, and 46,868 newly issued shares of the Company’s Series A Convertible Preferred Stock (“Series A Preferred Stock”), with a stated value of $ 46,868,000 , or $1,000 per share, for a total consideration of $ 50 million to acquire 100 % of the outstanding shares of Impact. The acquisition was done to add assets and a foundation of products with international market opportunities and demand, and which can be structured into long- term scalable, reoccurring license revenue within the DSS BioHealth line of business. Due to several factors, including a discount for illiquidity, the value of the Series A Preferred Stock was discounted from $ 46,868,000 to $ 35,187,000 , thus reducing the final consideration given to approximately $ 38,319,000 . The Company incurred approximately $ 295,000 in cost associated with the acquisition of Impact which were recorded as general and administrative expenses. As a result of the Share Exchange, Impact is now a wholly owned subsidiary of DSS BioHealth, the Company’s wholly owned subsidiary and operating results of the acquisition are included in the Company’s financial statements beginning August 21, 2020. Impact BioMedical has several subsidiaries that are not wholly owned by Impact and have an ownership percentage ranging from 63.6 % to 100 %. During the three and nine months ended September 30, 2021, Impact has incurred approximately $ 657,000 and $ 1,964,000 respectively of net losses, of which $ 115,000 and $ 281,000 respectively of loss incurred is attributable to non-controlling interest. Although Impact historically, and to date has not generated any revenues, the acquisition of Impact meets the definition of a business with inputs, processes and outputs, and therefore, the Company has concluded to account for this transaction in accordance with the acquisition method of accounting under Topic 805. American Pacific Bancorp. On September 9, 2021, the Company finalized a stock purchase agreement (the “SPA”) with American Pacific Bancorp (“APB”), which provided for an investment of $ 40,000,000 by the Company into APB for an aggregate of 6,666,700 shares of the APB’s Class A Common Stock, par value $ 0.01 per share. Subject to the terms and conditions contained in the SPA, the shares issued at a purchase price of $ 6.00 per share. As a result of this transaction, DSS owns approximately 53% of APB, and as a result its operating results will be included in the Company’s financial statements beginning September 9, 2021. The Company incurred approximately $ 36,000 in cost associated with the acquisition of APB which were recorded as general and administrative expenses. The acquisition of APB meets the definition of a business with inputs, processes and outputs, and therefore, the Company has concluded to account for this transaction in accordance with the acquisition method of accounting under Topic 805. Activity from September 9, 2021, to September 30, 2021, was not significant. The next largest shareholder of APB is Alset EHome International, Inc. (“AEI”). AEI’s Chairman and CEO, Heng Fai Chan, and a member of the AEI’s Board of Directors, Wu Wai Leung William, each serve on both the AEI Board and the Board of the Company. The CEO of the Company, Mr. Frank D. Heuszel, also has an approximate 2 The following summary, prepared on a proforma basis, combines the consolidated results of operations of the Company with those of APB as if the acquisition took place on January 1. The pro forma consolidated results include the impact of certain adjustments. Schedule of Business Acquisition, Pro Forma Information 2021 2020 Revenue $ 13,280,000 $ 10,233,000 Net (loss)/income $ (19,215,000 ) $ 1,778,000 Basic (loss)/earnings per share $ (0.46 ) $ 0.63 Diluted (loss)/earnings per share $ (0.46 ) $ 0.46 We are currently in the process of completing the purchase price accounting and related allocations associated with the acquisition of APB. The Company is in the process of completing valuations and useful lives for certain assets acquired in the transaction and the purchase price allocation will be completed with finalization of those valuations. We expect the preliminary purchase price accounting to be completed during the three months ending December 31, 2021. For the purposes of these financial statements, $ 16,945,000 20,301,000 3,400,000 1,250,000 1,900,000 330,000 101,000

Investments

Investments	9 Months Ended
	Sep. 30, 2021
Investments, All Other Investments [Abstract]
Investments	6. Investments Alset International Limited The Company owns 127,179,311 shares or approximately 7 % of the outstanding shares of Alset International Limited (“Alset Intl”), formerly named Singapore eDevelopment Limited (“SED”), a company incorporated in Singapore and publicly listed on the Singapore Exchange Limited as of September 30, 2021, and December 31, 2020. This investment is classified as a marketable security and is classified as long-term assets on the consolidated balance sheets as the Company has the intent and ability to hold the investments for a period of at least one year. The Chairman of the Company, Mr. Heng Fai Ambrose Chan, is the Executive Director and Chief Executive Officer of Alset Intl. Mr. Chan is also the majority shareholder of Alset Intl as well as the largest shareholder of the Company. The fair value of the marketable security as of September 30, 2021, and December 31, 2020, was approximately $ 5,990,000 and $ 6,830,000 respectively. During the three months ended September 30, 2021, the Company recorded unrealized gain on this investment of approximately $ 127,000 839,000 Sharing Services Global Corp. (“SHRG”) As of and through September 30, 2020, the Company classified its investment in Sharing Services Global Corp. (“SHRG”), a publicly traded company, as marketable equity security and measured it at fair value with gains and losses recognized in other income. In July 2020, through continued acquisition of common stock, as detailed below, the Company obtained greater than 20 Investments—Equity Method and Joint Ventures On July 22, 2020, Chan Heng Fai Ambrose, the Chairman of the Company’s board of directors, assigned a Stock Purchase and Share Subscription Agreement by and between Mr. Chan and SHRG, pursuant to which the Company purchased 30,000,000 shares of Class A common stock and 10,000,000 warrants to purchase Class A common stock for $ 3 million, causing the Company’s ownership in SHRG to exceed 20 %. The warrants have an average exercise price of $ 0.20 , immediately vested and may be exercised at any time commencing on the date of issuance and ending three years from such date. The warrants are considered an equity investment that is recorded at fair value with gains and losses recorded through earnings. These warrants have been recorded at the fair value of $ 324,000 as of September 30, 2021, as compared to $ 1,056,000 at December 31, 2020 on the Company’s consolidated balance sheet and are included in “other investments” with the decrease representing an unrealized loss of $ 224,000 and $ 732,000 respectively during the three and nine months ended September 30, 2021. As of July 22, 2020, the carrying value of the Company’s equity method investment exceeded our share of the book value of the investee’s underlying net assets by approximately $ 9,192,000 which represents primarily intangible assets in the form of a distributor lists and goodwill arising from acquisitions. These intangible assets have been valued at approximately $ 1,148,000 and $ 8,044,000 , respectively. The intangible asset arising from the distributor list has a five -year useful life. The Company has recorded amortization of $ 57,000 and $ 287,000 for the three- and nine-months ended September 30, 2021, respectively, on the consolidated statement of operations. On April 5, 2021, a subsidiary of the Company entered into a convertible promissory note (“SHRG Note”) with SHRG (see Note 3). The Company loaned the principal sum of $ 30,000,000 . Accordingly, in April 2021, the SHRG issued to the Company 27,000,000 shares of its Class A Common Stock, including 15,000,000 shares in payment of the loan origination fee and 12,000,000 shares in prepayment of interest for the first year. In addition, the Company received 150,000,000 warrants both issued and vested on April 5, 2021. These warrants have an exercise price of $ 0.22 and expire April 5, 2026 . As of the date of issuance the warrants the consideration paid allocated to the warrants amounted to approximately $ 14,957,000 . The warrants are considered an equity investment that is recorded at fair value with gains and losses recorded through earnings. These warrants have been recorded at the fair value of $ 6,212,000 as of September 30, 2021, on the Company’s consolidated balance sheet and are included in “other investments” with the decrease representing an unrealized loss of $ 2,780,000 and $ 8,745,000 , respectively, during the three- and nine-months ended September 30, 2021. As of September 30, 2021, the Company held 91,460,978 class A common shares equating to a 46.8 % ownership interest in SHRG. SHRG change its fiscal year end from April 30 to March 31, and due to this change and the difference in fiscal year ends between the two companies, effective for the three- and nine-month ended September 30, 2021, DSS changed its previous election to recognized its portion of SHRG’s earnings and losses on a two-month lag as of June 30, 2021 and has elected to recognize its portion of SHRG’s earnings and losses on a three-month lag basis going forward and utilized SHRG’s three-month ended June 30, 2021, reported results to recognize a loss on the equity method investment of approximately $ 1,645,000 . This change represents a change in accounting principle under ASC 250 “Accounting Changes and Error Corrections”. The aggregate fair value of the Company’s investment in SHRG at September 30, 2021 was approximately $ 8,688,000 . The following table represents SHRG operating results for the three-months ended June 30, 2021: Schedule of Operating Result Net sales $ 11,211,526 Gross profit $ 7,857,716 Operating loss $ (2,021,069 ) Loss before income taxes $ (2,800,118 ) Income tax benefit $ 747,889 Net loss $ (3,548,007 ) BMI Capital International LLC On September 10, 2020, the Company’s wholly owned subsidiary DSS Securities, Inc. entered into membership interest purchase agreement with BMI Financial Group, Inc. a Delaware corporation (“BMIF”) and BMI Capital International LLC, a Texas limited liability company (“BMIC”) whereas DSS Securities, Inc. purchased 14.9 100,000 10 24.9 20 BMIC is a broker-dealer registered with the Securities and Exchange Commission, is a member of the Financial Industry Regulatory Authority, Inc. (“FINRA”), and is a member of the Securities Investor Protection Corporation (“SIPC”). The Company’s chairman of the board and another independent board member of the Company also have ownership interest in this joint venture. Alset Title Company On or about August 28, 2020, the Company’s wholly owned subsidiary, DSS Securities, Inc. entered into a corporate venture to form and operate a real estate title agency, under the name of Alset Title Company, Inc, a Texas corporation (“ATC”). DSS Securities, Inc. shall own 70% of this venture with the other two shareholders being attorneys necessary to the state application and permitting process. ATC have initiated or have pending applications to do business in a number of states, including Texas, Tennessee, Connecticut, Florida, and Illinois. For the purpose of organization and the state application process, the Company’s CEO, who is a licensed attorney, has a stated non-compensated 15% ownership interest in the venture. There was minimal activity for the three and nine months ended September 30, 2021 BioMed Technologies Asia Pacific Holdings Limited On December 19, 2020, Impact BioMedical, a wholly-owned subsidiary of the Company, entered into a subscription agreement (the “Subscription Agreement”) with BioMed Technologies Asia Pacific Holdings Limited (“BioMed”), a limited liability company incorporated in the British Virgin Islands, pursuant to which the Company agreed to purchase 525 4.99 630,000 BioMed focuses on manufacturing natural probiotics, pursuant to which the Company will directly market, advertise, promote, distribute and sell certain BioMed products to resellers. The products to be distributed by the Company include BioMed’s PGut Premium Probiotics ® ® ® ® ® Under the terms of the Distribution Agreement, the Company will have exclusive rights to distribute the products within the United States, Canada, Singapore, Malaysia, and South Korea and non-exclusive distribution rights in all other countries. In exchange, the Company agreed to certain obligations, including mutual marketing obligations to promote sales of the products. This agreement is for ten years with an one year auto-renewal feature. Vivacitas Oncology, Inc. On March 15, 2021, the Company, through one of its subsidiaries, entered into a Stock Purchase Agreement (the “Vivacitas Agreement #1”) with Vivacitas Oncology Inc. (“Vivacitas”), to purchase 500,000 1.00 1,500,000 500,000 2,480,000 2,480,000 250,000 On April 1, 2021, the Company entered into an additional stock purchase agreement with Vivacitas (“Vivacitas Agreement #2”), whereas Vivacities wished to employ the service of the Chief Business Officer of Impact Biomedical, and in return for the services of this individual, Vivacitas shall issue to the Company, the aggregate purchase price for the Class A Common Shares of Vivacitas at the value of $ 1.00 120,000 On July 22, 2021, the Company exercised 1,000,000 1,000,000 19 Sentinel Brokers Company, Inc. On May 13, 2021, a Sentinel Brokers, LLC., subsidiary of the Company entered into a stock purchase agreement (“Sentinel Agreement”) to acquire a 24.9 % equity position of Sentinel Brokers Company, Inc. (“Sentinel”), a company registered in the state of New York, for the purchase price of $ 300,000 . During the three months ended September 30, 2021, the Company contributed and additional $ 750,000 1,050,000 50.1 % of the outstanding Class A Common Shares. Upon the exercising of this option, but no earlier than one year following the effective date the Sentinel Agreement, Sentinel has the option to sell the remaining 25 % to the Company. In consideration of purchase price investment in Sentinel, the Company is entitled to an additional 50.1% of the net profits of Sentinel. The Company currently accounts for its investment in Sentinel using the equity method in accordance with ASC Topic 323, as it currently owns 24.9 % of Sentinel. The Company currently accounts for its investment in Sentinel using the equity method in accordance with ASC Topic 323, Investments—Equity Method and Joint Ventures 11,000 for the three-months ended September 30, 2021, and a loss of $ 6,000 on the equity investment for the nine-months ended September 30, 2021. Sentinel is a broker-dealer operating primarily as a fiduciary intermediary, facilitating intuitional trading of municipal and corporate bonds as well as preferred stock, and is registered with the Securities and Exchange Commission, is a member of the Financial Industry Regulatory Authority, Inc. (“FINRA”), and is a member of the Securities Investor Protection Corporation (“SIPC”).

Short-Term and Long-Term Debt

Short-Term and Long-Term Debt	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Short-Term and Long-Term Debt	7. Short-Term and Long-Term Debt Revolving Credit Lines 800,000 2.0 May 31, 2021 0 On July 26, 2017, Premier Packaging entered into a Loan Agreement and accompanying Term Note Non-Revolving Line of Credit Agreement with Citizens pursuant to which Citizens agreed to lend up to $ 1,200,000 2 771,000 Equipment Line of Credit 900,000 2 2 July 28, 2021 0 Promissory Notes - 1,200,000 7,000 4.22 June 27, 2029 708,000 1,100,000 The Citizens credit facilities to each of the Company’s subsidiaries, Premier Packaging, contain various covenants including fixed charge coverage ratio, tangible net worth and current ratio covenants which are tested annually at December 31. For the year ended December 31, 2020, Premier Packaging was in compliance with the annual covenants. On March 2, 2020, AMRE entered into a $ 200,000 unsecured promissory note with LVAMPTE. The Note calls for interest to be paid annually on March 2 with interest fixed at 8.0 %. As of December 31, 2020, accrued interest is included in the outstanding balance. If not paid sooner, the entire unpaid principal balance is due in full on March 2, 2022 . As further incentive to enter into this Note, AMRE granted LVAMPTE warrants to purchase shares of common stock of AMRE (the “Warrants”). The amount of the warrants granted is the equivalent of the Note Principal divided by the Exercise Price. The Warrants are exercisable for four years and are exercisable at $ 5.00 per share (the “Exercise” Price). The value of the warrants is not considered to be material. The holder is a related party owned by the Chairman of the Company’s board of directors. As of September 30, 2021, the new promissory note, inclusive of unpaid interest, had a balance of $ 226,000 . During Q2 2020, the Company received loan proceeds for Premier Packaging, DSS Digital, and AAMI in the amount of approximately $ 1,078,000 100 969,000 100 On March 16, 2021, American Medical REIT, Inc. received loan proceeds in the amount of approximately $ 110,000 1 60 The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. These funds were used for payroll, benefits, rent, mortgage interest, and utilities On May 20, 2021, Premier Packaging entered into master loan and security agreement (“BOA Note”) with Bank of America, N.A. (“BOA”) to secure financing in an amount not to exceed $ 3,200,000 1,855,000 2.42 On June 18, 2021, AMRE Shelton, LLC., (“AMRE Shelton”) a subsidiary of AMRE, entered into a loan agreement (“Shelton Agreement”) with Patriot Bank, N.A. (“Patriot Bank”) in an amount up to $6,155,000, with the amount financed approximating $5,105,000. The Shelton Agreement contains monthly payments of principal and an initial interest 4.25%. The interest will be adjusted commencing on July 1, 2026 and continuing for the next succeeding 5 year period shall be determined one month prior to the change date and shall be an interest rate equal to two hundred fifty (250) basis points above the Federal Home Loan Bank Boston 5-Year/25-Year amortizing advance rate, but in no event less than 4.25% for the term of 120 months 2,829,000 191,000 4,699,000 185,000

Lease Liability

Lease Liability	9 Months Ended
	Sep. 30, 2021
Lease Liability
Lease Liability	8 . Lease Liability The Company has operating leases predominantly for operating facilities. As of September 30, 2021, the remaining lease terms on our operating leases range from less than one to five years Future minimum lease payments as of September 30, 2021, are as follows: Maturity of Lease Liability Schedule of Future Minimum Lease Payments Totals 2021 $ 59,000 2022 88,000 2023 50,000 2024 4,000 2025 4,000 2026 2,000 Total lease payments 207,000 Less: Imputed Interest (10,000 ) Present value of remaining lease payments $ 197,000 Current $ 122,000 Noncurrent $ 75,000 Weighted-average remaining lease term (years) 0.85 Weighted-average discount rate 5.4 %

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. Commitments and Contingencies The Apple Litigation On November 26, 2013, DSS Technology Management, Inc. (“DSSTM”) filed suit against Apple, Inc. (“Apple”) in the United States District Court for the Eastern District of Texas, for patent infringement (the “Apple Litigation”). The complaint alleges infringement by Apple of DSSTM’s patents that relate to systems and methods of using low power wireless peripheral devices. DSSTM is seeking a judgment for infringement, injunctive relief, and compensatory damages from Apple. On October 28, 2014, the case was stayed by the District Court pending a determination of Apple’s motion to transfer the case to the Northern District of California. On November 7, 2014, Apple’s motion to transfer the case to the Northern District of California was granted. On December 30, 2014, Apple filed two Inter Partes Review (“IPR”) petitions with the Patent Trial and Appeal Board (“PTAB”) for review of the patents at issue in the case. The PTAB instituted the IPRs on June 25, 2015. The California District Court then stayed the case pending the outcome of those IPR proceedings. Oral arguments of the IPRs took place on March 15, 2016, and on June 17, 2016, PTAB ruled in favor of Apple on both IPR petitions. DSSTM then filed an appeal with the U.S. Court of Appeals for the Federal Circuit (the “Federal Circuit”) seeking reversal of the PTAB decisions. Oral arguments for the appeal were held on August 9, 2017. On March 23, 2018, the Federal Circuit reversed the PTAB, finding that the PTAB erred when it found the claims of U.S. Patent No. 6,128,290 to be unpatentable. The Federal Circuit affirmed its decision on July 12, 2018, when it denied Apple’s petition for panel rehearing of the Federal Circuit’s Opinion and Judgment issued on March 23, 2018. On July 27, 2018, the District Court judge lifted the Stay resuming the litigation, which had a trial date set for the week of February 24, 2020. On January 14, 2020, the Court in the case DSS Technology Management, Inc. v. Apple, Inc., 4:14-cv-05330-HSG pending in the Northern District of California issued an order that denied DSS’ motion to amend its infringement contentions. In the same Order, the Court granted Apple’s motion to strike DSS’ infringement expert report. DSS filed a motion for leave to file a motion for reconsideration of the Court’s order denying DSS the right to amend its infringement contentions and motion to strike DSS infringement expert report. On February 18, 2020, the Court denied DSS’s motion for leave to file a motion for reconsideration. On February 24, 2020, the Court signed a Final Judgment stipulating that Apple was “entitled to a judgment of non-infringement of U.S. Patent No. 6,128,290 as a matter of law.” On March 10, 2020, DSS filed an appeal of this Final Judgment to the United States Court of Appeals for the Federal Circuit under DSS Technology Management v. Apple, Federal Circuit Docket no. 2020-1570. On April 27, 2021, the Court of Appeals heard oral argument, and on April 30, 2021, the Court affirmed the District Court’s judgment. After considering all factors the Company has elected to not pursue any further appeals on this matter. Case is deemed closed. The Ronaldi Litigation In April 2019 DSS commenced an action in New York State Supreme Court, Monroe County, Index No. E2019003542, against Jeffrey Ronaldi, our former Chief Executive Officer. This New York action seeks a declaratory judgment that, contrary to informal claims made by him, Mr. Ronaldi’s employment agreement with us expired by its terms and that he is not entitled to any cash bonuses or other unpaid amounts. The lawsuit also seeks an injunction against Mr. Ronaldi from interfering with any of DSS’ IP litigation. Mr. Ronaldi subsequently commenced an action against DSS in the Superior Court of California, County of San Diego, on November 8, 2019, under case number 37-2019-00059664-CU-CO-CTL, in which he alleged that DSS terminated his employment in April 2019 in order to avoid paying him certain employment-related amounts. DSS was successful in dismissing the California case and consolidating it with the action pending in Monroe County, New York. Mr. Ronaldi asserted counterclaims in the Monroe County, New York action similar to those he originally brought in California. Mr. Ronaldi claims that his termination violated an alleged employment agreement or implied-in-fact employment agreement and that he should have remained employed through 2019. Mr. Ronaldi seeks to recover: (i) $144,658 in wages from April 11, 2019 through December 31, 2019; (ii) $769 in alleged unpaid based salary for time worked before April 11, 2019; (iii) $15,385 in alleged paid time off compensation; (iv) $3,077 in alleged unpaid sick time compensation; (v) $26,077 in waiting-time penalties; (vi) $91,000 in unspecified expense reimbursement; (vii) $300,000 in alleged cash bonuses ($100,000 per year) based on DSS’s performance in 2017, 2018 and 2019; and (viii) a $450,000 performance bonus based on the result of certain alleged net proceeds from patent infringement litigation. He further claims an interest in any recovery in DSS Technology Management v. Apple, Inc., Case No. 4:14-cf05330-HSG. The parties are now engaged in discovery Additionally, on March 2, 2020, DSS and DSSTM filed a second litigation action against Jeffrey Ronaldi in the State of New York, Supreme Court, County of Monroe, Document Security Systems, Inc. and DSS Technology Management, Inc. vs. Jeffrey Ronaldi, Index No.: 2020002300, alleging acts of self-dealing and conflicts of interest while he served as CEO of both DSS and DSS TM. Mr. Ronaldi filed a Notice of Removal of this civil litigation to the United States District Court for the Western District of New York where it was assigned Case No. 6:20-cv-06265-EAW. Mr. Ronaldi filed a motion seeking to compel DSS to advance his legal fees to defend the action, which motion was fully briefed as of June 30, 2020, and remains pending and undecided. On March 16, 2021, the Western District of New York granted Mr. Ronaldi’s motion to have his defense costs advanced to him during the pendency of the action as they are incurred. On March 26, 2021, Mr. Ronaldi applied to the court for reimbursement of $ 160,896 Maiden Biosciences Litigation On February 15, 2021, Maiden Biosciences, Inc. (“Maiden”) commenced an action against Document Security Stems, Inc. (“DSS”), Decentralized Sharing Systems, Inc. (“Decentralized”), HWH World, Inc. (“HWH”), RBC Life International, Inc., RBC Life Sciences, Inc (“RBC”)., Frank D. Heuszel (“Heuszel”), Steven E. Brown, Clinton Howard, and Andrew Howard (collectively, “Defendants”). The lawsuit is currently pending in the United States District Court Northern District of Texas, Dallas Division, and is styled and numbered Maiden Biosciences, Inc. v. Document Security Stems, Inc., et al., Case No. 3:21-cv-00327. This lawsuit relates to two promissory notes executed by RBC in the 4 th Decentralized and HWH, totaling approximately $800,000. Maiden, a 2020 default judgment creditor of RBC, in the principal amount of $4,329,000, now complains about those notes, the funding of those notes, the subsequent default of those notes by RBC, and HWH and Decentralize’s subsequent Article 9 foreclosure or deed-in-lieu debt conveyances. In the instant lawsuit, Maiden asserts claims against Defendants for unjust enrichment, fraudulent transfer under the Texas Uniform Fraudulent Transfer Act, and violation of the Racketeer Influenced and Corrupt Organizations Act. Maiden also seeks a judgment from the court declaring: “(1) Defendants lacked a valid security interest in RBC and RBC Subsidiaries’ assets and therefore lacked the authority to sell the assets during the public foreclosure sale; (2) Defendant Heuszel’s low bid at the public foreclosure sale was invalid and void; (3) the public foreclosure sale was conducted in a commercially unreasonable manner; and (4) Defendants do not have the legal authority to transfer RBC and RBC’s Subsidiaries assets to Heuszel and HWH.” Maiden seeks to recover from Defendants: (1) treble damages or, alternatively, damages in the amount of their underlying judgment plus the other creditors’ claims or the value of the assets transferred, whichever is less, plus punitive or exemplary damages; (2) pre and post-judgment interest; and (3) attorneys’ fees and cost On March 30, 2021, Defendants DSS, Decentralized, HWH, RBC Life International, Inc., and Heuszel filed a motion to dismiss seeking to dismiss Maiden’s unjust enrichment, exemplary damages, and RICO claims against DSS, Decentralized, HWH, RBC Life International, Inc., and Heuszel, as well as Maiden’s fraudulent transfer claims against DSS and RBC International, Inc. On August 9, 2021, the Court then entered an order granting in part the motion to dismiss filed on behalf of DSS, Decentralized, HWH, RBC Life International, Inc., and Heuszel. Among other things, the Court held that Maiden failed to plausibly plead certain causes of action, including (1) the civil RICO claim against DSS, Decentralized, HWH, RBC Life International, Inc., and Heuszel, (2) the TUFTA claim against DSS, and (3) the unjust enrichment claim against DSS and RBC Life International, Inc. Notably, the Court declined the request to dismiss the TUFTA claim against RBC Life International, Inc. The Court granted Maiden leave to file an amended complaint. Maiden’s deadline to do so is Monday, September 6, 2021. The Company intends to vigorously defend its position. On September 3, 2021, Maiden filed its amended complaint, asserting a single cause of action against the DSS Defendants and RBC for an alleged TUFTA violation. Generally, Maiden is seeking the same relief requested in its original complaint. Maiden, however, has abandoned its request for treble damages. On September 17, 2021, the DSS Defendants filed a motion to dismiss the amended complaint seeking to dismiss Maiden’s TUFTA claim to the extent it seeks to avoid a transfer of assets owned by any of RBC’s subsidiaries, including but not limited to RBC Life Sciences USA, Inc. Further, the motion to dismiss also seeks the dismissal of Maiden’s TUFTA claim against Heuszel. The DSS Defendants’ motion to dismiss the amended complaint will be ripe for determination on or after October 22, 2021. Trial is currently set for December 5, 2022 on the Court’s two-week docket. In addition to the foregoing, we may become subject to other legal proceedings that arise in the ordinary course of business and have not been finally adjudicated. Adverse decisions in any of the foregoing may have a material adverse effect on our results of operations, cash flows or our financial condition. The Company accrues for potential litigation losses when a loss is probable and estimable.

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Stockholders’ Equity	10. Stockholders’ Equity Sales of Equity In connection with the Share Exchange for Impact BioMedical described in Note 5, on August 18, 2020, the Company filed a Certificate of Amendment of its Certificate of Incorporation (the “Certificate of Amendment”) to increase the number of authorized shares of the Company, including 47,000 0.02 47,000 Holders of the Series A Preferred Stock have no voting rights, except as required by applicable law or regulation, and no dividends accrue or are payable on the Series A Preferred Stock. The holders of Series A Preferred Stock are entitled to a liquidation preference at a liquidation value of $ 1,000 46,868,000 1,000 6.48 154.32 19.99 7,232,670 4,293 662,500 35,316 5,450,000 7,259 1,120,170 On January 19, 2021, the Company entered into an underwriting agreement, as amended by Amendment No. 1 effective as of January 19, 2021 (the “Jan. 2021 Underwriting Agreement”), with Aegis Capital Corp., as representative of the underwriters, which provided for the issuance and sale by the Company and the purchase by the underwriters, in a firm commitment underwritten public offering (the “Jan. 2021 Offering”), of 6,666,666 0.02 3.60 1,000,000 24.9 On February 4, 2021, the Company entered into an underwriting agreement (the “Feb. 2021 Underwriting Agreement”) with Aegis Capital Corp., as representative of the underwriters named therein, which provided for the issuance and sale by the Company and the purchase by the underwriters, in a firm commitment underwritten public offering (the “Feb. 2021 Offering”), of 12,319,346 0.02 2.80 1,847,901 36.14 On May 26, 2021, the Company entered into an underwriting agreement (the “May 2021 Underwriting Agreement”) with Aegis Capital Corp., as representative of the underwriters named therein, which provided for the issuance and sale by the Company and the purchase by the underwriters, in a firm commitment underwritten public offering (the “May 2021 Offering”), of 29,000,000 0.02 1.50 4,350,000 45.75 On September 3, 2021, DSS entered into a subscription agreement (the “AEI Subscription Agreement”) with AEI, which provided for an investment of up to $ 15,000,000 12,156,000 0.02 1.234 Stock-Based Compensation - 13,000 42,000 .01 On June 4, 2020, the Company entered into an agreement with an investor relations firm to provide services over a 14-month period in exchange for 21,000 210,000 15,000 105,000

Discontinued Operations

Discontinued Operations	9 Months Ended
	Sep. 30, 2021
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	11. Discontinued Operations On August 14, 2020, the Company entered into a final Asset Purchase Agreement and the Company terminated its production and office personnel and maintained only a few employees to assist in and facilitate the sale of its assets. The financial results for these subsidiaries have been presented as discontinued operations in the accompanying consolidated financial statements. The consideration paid to the Company under the Asset Purchase Agreement for the sale of the assets included a one-time cash payment of $ 683,000 and an additional contingent earn-out payment of an aggregate amount of up to $ 517,000 based on future quarterly gross revenue of the business to be conducted by the buyer with the sold assets. Consistent with the Company’s policy for accounting for gain contingencies, the earn out will be recorded when determined realizable. As of September 30, 2021, the Company has recognized $ 390,000 of this earn out, all of which was recognized during the year ended December 31, 2020. The net effect of all assets disposed of resulted in a net loss of $ 111,000 to the third quarter 2020. These amounts are included in Loss from Discontinued Operations. Included in its Right-of-use assets is the lease of the Company’s facility in Brisbane, Ca. In April 2021, the Company terminated this lease with the landlord effective March 31, 2021, and therefore, wrote off the asset and corresponding liability associated with the lease at March 31, 2021. As of December 31, 2020, $ 744,000 was record as non-current asset held for sale – discontinued operations on the consolidated balance sheet. Also recorded was $ 240,000 of current liabilities held for sale – discontinued operations and $ 505,000 of non-current liabilities held for sale – discontinued operations. The Company has incurred $ 204,000 The following table shows the results of operations of the discontinued operation. Schedule of Discontinued Operations Plastic Printing Professionals, Inc. Consolidated Statements of Operations and Comprehensive Loss - Discontinued Operations (unaudited) For the Three Months Ended For the Nine Months Ended September 30, 2020 September 30, 2020 Revenue: Printed products $ 243,000 $ 1,626,000 Total revenue 243,000 1,626,000 Costs and expenses: Cost of revenue, exclusive of depreciation and amortization 382,000 1,644,000 Selling, general and administrative (including stock-based compensation) 130,000 715,000 Depreciation and amortization 37,000 152,000 Impairment of goodwill - 685,000 Total costs and expenses 549,000 3,196,000 Operating loss (306,000 ) (1,570,000 ) Other income (expense): Interest expense (7,000 ) (21,000 ) Loss on sale of assets held for sale (111,000 ) (111,000 ) Income (loss) before income taxes (424,000 ) (1,702,000 ) Income tax expense (benefit) - - Income (loss) from discontinued operations (424,000 ) (1,702,000 ) On May 7, 2021, the Company completed the sale of 100 5,000,000 3 1.5 0.5 0.5 2,226,000 The following tables show the major classes of assets and liabilities held for sale and results of operations of the discontinued operation. Schedule of Assets and Liabilities Held for Sale DSS Digital, Inc. Consolidated Balance Sheets - Assets and Liabilities Held for Sale September 30, 2021 December 31, 2020 unaudited unaudited ASSETS Current assets: Cash $ $ 43,000 Accounts receivable, net - 321,000 Prepaid expenses and other current assets - 167,000 Total current assets - 531,000 Property, plant and equipment, net - 46,000 Total assets - 577,000 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ - $ 25,000 Accrued expenses and deferred revenue - 9,000 Total current liabilities - 34,000 DSS Digital, Inc. Consolidated Statements of Operations - Discontinued Operations (unaudited) 2021 2020 2021 2020 For the Three Months Ended For the Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Revenue: Technology sales, services and licensing $ - $ 483,000 $ 535,000 $ 1,315,000 Total revenue - 483,000 535,000 1,315,000 Costs and expenses: Cost of revenue, exclusive of depreciation and amortization - 70,000 87,000 209,000 Selling, general and administrative (including stock-based compensation) - 226,000 338,000 835,000 Depreciation and amortization - 4,000 5,000 12,000 Total costs and expenses - 300,000 430,000 1,056,000 Operating income - 183,000 105,000 259,000 Income before income taxes - 183,000 105,000 259,000 Income tax expense (benefit) - - - - Income from discontinued operations $ - $ 183,000 $ 105,000 $ 259,000

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	12. Income Taxes Our effective tax rate for the nine-months ended September 30, 2021, was 17.3 % on continuing operations. There was no tax provision for September 30, 2020, due to the expected tax benefit from net operating losses (NOLs) being fully offset by an increase in the valuation allowance. The Company also recorded a discrete tax expense in the nine-month period ended September 30, 2021, of $ 83,000 related to the sale of DSS Digital which is included in discontinued operations. This discrete item relates to the tax effect of the GAAP over tax basis of a subsidiary that was sold in the nine-month period ended September 30, 2021. This discrete tax expense is included in the total tax provision of $ 596,000 which is in discontinued operations. As of December 31, 2020, the Company has domestic net operating loss (“NOL”) carryforwards of approximately $ 56.7 2.1 As of September 30, 2021, no benefit for losses incurred by our foreign subsidiaries have been recorded as those losses are not anticipated to provide any tax benefits in future periods. There were no As a result of our operations, we file income tax returns in various jurisdictions including U.S. federal, U.S. state and foreign jurisdictions. We are routinely subject to examination by taxing authorities in these various jurisdictions. At September 30, 2021, there are no ongoing income tax audits.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	9 Months Ended
	Sep. 30, 2021
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	13. Supplemental Cash Flow Information The following table summarizes supplemental cash flows for the nine-months ended September 30, 2021, and 2020: Schedule of Supplemental Cash Flow Information 2021 2020 Cash paid for interest $ 139,000 $ 73,000 Non-cash investing and financing activities: Termination of right of use lease asset $ (744,000 ) $ - Termination of right of use lease liability $ 744,000 $ - Shares received for loan origination fee $ (3,000,000 ) $ - Shares received for prepaid loan interest $ (2,440,000 ) $ - Series A Preferred Shares issued for Impact BioMedical $ - $ 35,187,000 Common Shares issued for Impact Biomedical $ - $ 3,132,000 Long-lived assets acquired through settlement of notes receivable $ - $ 838,000 Acquisition of APB net assets $ 38,765,000 - Shares issued for marketing services $ - $ 210,000

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Segment Information	14. Segment Information The Company’s nine businesses lines are organized, managed and internally reported as five operating segments. One of these operating segments, Premier Packaging, is the Company’s packaging and printing group. Premier Packaging operates in the paper board folding carton, smart packaging, and document security printing markets. It markets, manufactures, and sells mailers, photo sleeves, sophisticated custom folding cartons, and complex 3-dimensional direct mail solutions. These products are designed to provide functionality and marketability while also providing counterfeit protection. A second, BioHealth Group, invests in, or acquires companies in the biohealth and biomedical fields, including businesses focused on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. This division is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. The BioHealth Group is also targeting unmet, urgent medical needs. A third operating segment, Securities and Fintech Group (“Securities”) was established to develop and/or acquire assets and investments in the securities trading and/or funds management arena. Further, Securities, in partnership with recognized global leaders in alternative trading systems, intends to own and operate in the US a single or multiple vertical digital asset exchanges for securities, tokenized assets, utility tokens, stable coins and cryptocurrency via a digital asset trading platform using blockchain technology. The scope of services within this section is planned to include asset issuance and allocation (securities and cryptocurrency), FPO, IPO, ITO, PPO, STO and UTO listings on a primary market(s), asset digitization/tokenization (securities, currency and cryptocurrency), and the listing and trading of digital assets (securities and cryptocurrency) on a secondary market(s). Also in this segment is the Company’s real estate investment trust (“REIT”), organized for the purposes of acquiring hospitals and other acute or post-acute care centers from leading clinical operators with dominant market share in secondary and tertiary markets, and leasing each property to a single operator under a triple-net lease. the REIT was formed to originate, acquire, and lease a credit-centric portfolio of licensed medical real estate. The fourth segment, Direct Marketing/Online Sales Group, provides services to assist companies in the emerging growth gig business model of peer-to-peer decentralized sharing marketplaces. It specializes in marketing and distributing its products and services through its subsidiary and partner network, using the popular gig economic marketing strategy as a form of direct marketing. Direct marketing products include, among other things, nutritional and personal care products sold throughout North America, Asia Pacific and Eastern Europe. The fifth business line, Investment Banking, is organized for the purposes of being a financial network holding company, focused providing commercial loans and on acquiring equity positions in (i) undervalued commercial bank(s), bank holding companies and nonbanking licensed financial companies operating in the United States, South East Asia, Taiwan, Japan and South Korea, and (ii) companies engaged in—nonbanking activities closely related to banking, including loan syndication services, mortgage banking, trust and escrow services, banking technology, loan servicing, equipment leasing, problem asset management, SPAC (special purpose acquisition company) consulting, and advisory capital raising services. From this financial platform, the Company shall provide an integrated suite of financial services for businesses that shall include commercial business lines of credit, land development financing, inventory financing, third party loan servicing, and services that address the financial needs of the world Gig Economy. Our segment structure presented below represents a change from the prior year for the inclusion of our BioHealth Group, Securities, and Investment Banking segments and the removal of our Plastics segment, Digital Group and IP Technology Management segment as the Plastics segment was discontinued in 2020, DSS Digital was sold and discontinued in May 2021 and activities surrounding our IP Technology Management segment have significantly decreased. The amounts for these segments have been included in the Corporate reporting segment for the three- and nine-months ended September 30, 2021 and 2020, as necessary, below for reconciliation purposes. Approximate information concerning the Company’s operations by reportable segment for the three and nine months ended September 30, 2021, and 2020 is as follows. The Company relies on intersegment cooperation and management does not represent that these segments, if operated independently, would report the results contained herein: Schedule of Operations by Reportable Segment Three Months Ended September 30, 2021 Packaging and Printing Investment Banking Direct Marketing Biohealth Group Securities Corporate Total Revenue $ 3,416,000 $ - $ 966,000 $ - $ 184,000 $ - $ 4,566,000 Depreciation and amortization 152,000 - 100,000 278,000 135,000 74,000 739,000 Interest expense 11,000 - - - 37,000 (17,000 ) 31,000 Stock based compensation 1,000 - - - - 12,000 13,000 Net income (loss) from continuing operations 358,000 64,000 (1,304,000 ) (647,000 ) (835,000 ) (4,311,000 ) (6,675,000 ) Capital expenditures 1,399,000 - - - 186,000 55,000 1,640,000 Identifiable assets 24,752,000 60,388,000 43,695,000 55,848,000 11,376,000 23,017,000 219,076,000 Three Months Ended September 30,2020 Packaging and Printing Direct Marketing Biohealth Group Securities Corporate Total Revenue $ 2,971,000 $ 715,000 $ $ $ - $ 3,686,000 Depreciation and amortization 165,000 1,000 - - 78,000 244,000 Interest expense 24,000 - - - 5,000 29,000 Stock based compensation 3,000 - - - 125,000 128,000 Net income (loss) from continuing operations 136,000 (1,139,000 ) - 6,185,000 5,182,000 Capital expenditures 1,000 1,000 - - - 2,000 Identifiable assets 10,013,000 1,809,000 - - 68,305,000 80,127,000 Nine Months Ended September 30, 2021 Packaging and Printing Investment Banking Direct Marketing Biohealth Group Securities Corporate Total Revenue $ 10,652,000 $ - $ 2,382,000 $ - $ 184,000 $ - $ 13,218,000 Depreciation and amortization 459,000 - 419,000 835,000 134,000 228,000 2,075,000 Interest expense 49,000 - 2,000 1,000 87,000 18,000 157,000 Stock based compensation 2,000 - - - - 40,000 42,000 Net income (loss) from continuing operations 641,000 64,000 (9,088,000 ) (1,955,000 ) (1,066,000 ) (10,058,000 ) (21,462,000 ) Capital expenditures 2,621,000 - 6,000 - 6,750,000 4,000 9,381,000 Identifiable assets 24,752,000 60,388,000 43,695,000 55,848,000 11,376,000 23,017,000 219,076,000 Nine Months Ended September 30,2020 Packaging and Printing Direct Marketing Biohealth Group Securities Corporate Total Revenue $ 8,409,000 $ 1,793,000 $ $ $ - $ 10,202,000 Depreciation and amortization 584,000 1,000 - - 227,000 812,000 Interest expense 79,000 - - - 23,000 102,000 Stock based compensation 11,000 - - - 170,000 181,000 Net income (loss) from continuing operations 222,000 (960,000 ) - - 4,249,000 3,511,000 Capital expenditures 91,000 1,000 - - 1,000 93,000 Identifiable assets 10,013,000 1,809,000 - - 68,305,000 80,127,000 The following tables disaggregate our business segment revenues by major source: Schedule of Disaggregation of Revenue Printed Products Revenue Information: Three months ended September 30, 2021 Packaging Printing and Fabrication $ 3,373,000 Commercial and Security Printing 43,000 Total Printed Products $ 3,416,000 Three months ended September 30, 2020 Packaging Printing and Fabrication $ 2,568,000 Commercial and Security Printing 403,000 Total Printed Products $ 2,971,000 Nine months ended September 30, 2021 Packaging Printing and Fabrication $ 10,428,000 Commercial and Security Printing 224,000 Total Printed Products $ 10,652,000 Nine months ended September 30, 2020 Packaging Printing and Fabrication $ 7,635,000 Commercial and Security Printing 774,000 Total Printed Products $ 8,409,000 Direct Marketing Three months ended September 30, 2021 Direct Marketing Internet Sales $ 966,000 Total Direct Marketing $ 966,000 Three months ended September 30, 2020 Direct Marketing Internet Sales $ 715,000 Total Direct Marketing $ 715,000 Nine months ended September 30, 2021 Direct Marketing Internet Sales $ 2,382,000 Total Direct Marketing $ 2,382,000 Nine months ended September 30, 2020 Direct Marketing Internet Sales $ 1,793,000 Total Direct Marketing $ 1,793,000 Securities Three months ended September 30, 2021 Rental Income $ 184,000 Total Rental Income $ 184,000 Three months ended September 30, 2020 Rental Income $ - Total Rental Income $ - Nine months ended September 30, 2021 Rental Income $ 184,000 Total Rental Income $ 184,000 Nine months ended September 30, 2020 Rental Income $ - Total Rental Income $ -

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	15. Subsequent Events On October 13, 2021, DFMI entered into a loan agreement with LVAM, whereby DFMI would lend to LVAM a principal sum not to exceed $ 3,000,000 with interest charged at a variable rate and maturing on October 12, 2022 with an auto renewal period of three months. On November 4, 2021, AMRE acquired three medical facilities located in Fort Worth, Texas, Plano, Texas, and Pittsburgh, Pennsylvania for a purchase price of $ 62,000,000 The medical facilities acquired by AMRE are currently under an 18 eleven years 320,000 The purchase price was funded through multiple borrowing facilities, including $ 13,940,000 8,350,000 8.00 payable in cash quarterly in arrears commencing on the 29th day of January 2022, and continue on the 29th day of each April, July, October and January thereafter through maturity At the option of the Company, the unpaid principal and interest balance on the note may be converted, in whole or in part, at any time on or before the maturity date, into fully-paid and non-assessable shares of common stock par value $0.001 per share of common stock of AMRE at a conversion rate equal to $ 10.00 These facilities have varying maturity dates through November 2023

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Principles of Consolidation	Principles of Consolidation
Use of Estimates	Use of Estimates
Reclassifications	Reclassifications - Certain amounts on the accompanying consolidated balance sheets for the year ended December 31, 2020, have been reclassified to conform to current period presentation. Restricted cash Notes receivable, unearned interest, and related recognition The Company records all future payments of principal and interest on notes as notes receivable, which are then offset by the amount of any related unearned interest income. For financial statement purposes, the Company reports the net investment in the notes receivable on the consolidated balance sheet as current or long-term based on the maturity date of the underlying notes. Such net investment is comprised of the amount advanced on the loans, adjusting for net deferred loan fees or costs incurred at origination, amounts allocated to warrants received upon origination, and any payments received in advance. The unearned interest is recognized over the term of the notes and the income portion of each note payment is calculated so as to generate a constant rate of return on the net balance outstanding. Net deferred loan fees or costs, together with discounts recognized in connection with warrants acquired at origination, are accreted as an adjustment to yield over the term of the loan.
Investments	Investments For equity method investments, the Company regularly reviews its investments to determine whether there is a decline in fair value below book value. If there is a decline that is other-than-temporary, the investment is written down to fair value. See Note 6 for further discussion on investments.
Fair Value of Financial Instruments	Fair Value of Financial Instruments - ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets. ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts reported in the balance sheet of cash and cash equivalents, accounts receivable, prepaids, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. Marketable securities classify as a Level 1 fair value financial instrument. The fair value of notes receivable approximates their carrying value as the stated or discounted rates of the notes do reflect recent market conditions. The fair value of revolving credit lines notes payable and long-term debt approximates their carrying value as the stated or discounted rates of the debt reflect recent market conditions. The fair value of investments where the fair value is not considered readily determinable, are carried at cost.
Impairment of Long-Lived Assets and Goodwill	Impairment of Long-Lived Assets and Goodwill
Related Party Liabilities	Related Party Liabilities – On April 1, 2020 the Company’s HWH World, Inc subsidiary has a service agreement with HWH Korea, a subsidiary of Alset International Limited (“Alset Intl.”) (formally Singapore eDevelopment Limited). The Chairman of the Company, Mr. Heng Fai Ambrose Chan, is the Executive Director and Chief Executive Officer of Alset Intl. Mr. Chan is also the majority shareholder of Alset Intl as well as the largest shareholder of the Company. The Company also owns approximately 127,179,000 shares of Alset Intl, a company publicly listed on the Singapore Exchange Limited. This service agreement will allow HWH Korea to utilize the Company’s merchant account in connection with their direct marketing network with periodic remittance of the cash collected to them for a fee of 2.5 % of amounts collected. As of September 30, 2021, the Company had collected approximately $ 0 as compared to $ 1,100,000 as of December 31, 2020, on behalf of HWH Korea, which is included in Accrued expenses and deferred revenue on the consolidated balance sheet. There were no amounts outstanding to this related party at September 30, 2021.
Acquisitions	Acquisitions Business combinations and non-controlling interests are recorded in accordance with FASB ASC 805 Business Combinations. Under the guidance, the assets and liabilities of the acquired business are recorded at their fair values at the date of acquisition and all acquisition costs are expensed as incurred. The excess of the purchase price over the estimated fair values is recorded as goodwill. If the fair value of the assets acquired exceeds the purchase price and the liabilities assumed, then a gain on acquisition is recorded. The application of business combination accounting requires the use of significant estimates and assumptions. Acquisition of assets are recorded at their relative fair value based on total accumulated costs of the acquisition. Direct acquisition-related costs are capitalized as a component of the acquired assets. This includes all costs related to finding, analyzing and negotiating a transaction. The allocation of the purchase price is an area that requires judgment and significant estimates. Tangible and intangible assets include land, building and improvements, furniture, fixtures and equipment, acquired above market and below market leases, in-place lease value (if applicable). Acquisition-date fair values of assets and assumed liabilities are determined based on replacement costs, appraised values, and estimated fair values using methods similar to those used by independent appraisers and that use appropriate discount and/or capitalization rates and available market information.
Discontinued Operations	Discontinued Operations On May 7, 2021, the Company completed the sale of 100
(Loss)	(Loss) Earnings Per Common Share - The Company presents basic and diluted (loss) earnings per share. Basic (loss) earnings per share reflect the actual weighted average of shares issued and outstanding during the period. Diluted (loss) earnings per share are computed including the number of additional shares from outstanding warrants, stock options and preferred stock that would have been outstanding if dilutive potential shares had been issued and is calculated utilizing the treasury stock method. In a loss period, the calculation for basic and diluted (loss) earnings per share is the same, as the impact of potential common shares is anti-dilutive.
Concentration of Credit Risk	Concentration of Credit Risk - During the nine months ended September 30, 2021, two customers accounted for 43 % of our consolidated revenue. As of September 30, 2021, these two customers accounted for 73 % of our consolidated trade accounts receivable balance. During the nine-months ended September 30, 2020, these two customers accounted for 37 % of our consolidated revenue and 48 % of our consolidated trade accounts receivable balance.
Income Taxes	Income Taxes
Recent Accounting Pronouncements	Recent Accounting Pronouncements
Impact of COVID-19 Outbreak	Impact of COVID-19 Outbreak

Financial Instruments (Tables)

Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2021
Investments, All Other Investments [Abstract]
Schedule of Cash and Marketable Securities by Significant Investment Category	The following tables show the Company’s cash, cash equivalents, restricted cash, and marketable securities by significant investment category as of September 30, 2021, and December 31, 2020: Schedule of Cash and Marketable Securities by Significant Investment Category 2021 Adjusted Cost Unrealized Gain/(Loss) Fair Value Cash, Cash Equivalents, and Restricted Cash Marketable Securities Investments Cash and cash equivalents $ 51,438,000 $ - $ 51,438,000 $ 51,438,000 $ - $ - Restricted cash 350,000 - 350,000 350,000 - - Level 1 Money Market Funds 17,699,000 - 17,699,000 17,699,000 - - Marketable Securities 6,608,000 2,599,000 9,207,000 - 9,207,000 - Level 2 Warrants 15,657,000 (9,121,000 ) 6,536,000 - - 6,536,000 Total $ 91,752,000 $ (6,522,000 ) $ 85,230,000 $ 69,487,000 $ 9,207,000 $ 6,536,000 2020 Adjusted Cost Unrealized Gain/(Loss) Fair Value Cash and Cash Equivalents Marketable Securities Investment Cash and cash equivalents $ 1,690,000 $ - $ 1,690,000 $ 1,690,000 $ - $ - Level 1 Money Market Funds 3,493,000 - 3,493,000 3,493,000 - - Marketable Securities 5,641,000 3,495,000 9,136,000 - 9,136,000 - Level 2 Warrants 700,000 356,000 1,056,000 - - 1,056,000 Total $ 11,524,000 $ 3,851,000 $ 15,375,000 $ 5,183,000 $ 9,136,000 $ 1,056,000

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Schedule of Business Acquisition, Pro Forma Information	The following summary, prepared on a proforma basis, combines the consolidated results of operations of the Company with those of APB as if the acquisition took place on January 1. The pro forma consolidated results include the impact of certain adjustments. Schedule of Business Acquisition, Pro Forma Information 2021 2020 Revenue $ 13,280,000 $ 10,233,000 Net (loss)/income $ (19,215,000 ) $ 1,778,000 Basic (loss)/earnings per share $ (0.46 ) $ 0.63 Diluted (loss)/earnings per share $ (0.46 ) $ 0.46

Investments (Tables)

Investments (Tables)	9 Months Ended
	Sep. 30, 2021
Investments, All Other Investments [Abstract]
Schedule of Operating Result	The following table represents SHRG operating results for the three-months ended June 30, 2021: Schedule of Operating Result Net sales $ 11,211,526 Gross profit $ 7,857,716 Operating loss $ (2,021,069 ) Loss before income taxes $ (2,800,118 ) Income tax benefit $ 747,889 Net loss $ (3,548,007 )

Lease Liability (Tables)

Lease Liability (Tables)	9 Months Ended
	Sep. 30, 2021
Lease Liability
Schedule of Future Minimum Lease Payments	Maturity of Lease Liability Schedule of Future Minimum Lease Payments Totals 2021 $ 59,000 2022 88,000 2023 50,000 2024 4,000 2025 4,000 2026 2,000 Total lease payments 207,000 Less: Imputed Interest (10,000 ) Present value of remaining lease payments $ 197,000 Current $ 122,000 Noncurrent $ 75,000 Weighted-average remaining lease term (years) 0.85 Weighted-average discount rate 5.4 %

Discontinued Operations (Tables

Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2021
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Discontinued Operations	The following table shows the results of operations of the discontinued operation. Schedule of Discontinued Operations Plastic Printing Professionals, Inc. Consolidated Statements of Operations and Comprehensive Loss - Discontinued Operations (unaudited) For the Three Months Ended For the Nine Months Ended September 30, 2020 September 30, 2020 Revenue: Printed products $ 243,000 $ 1,626,000 Total revenue 243,000 1,626,000 Costs and expenses: Cost of revenue, exclusive of depreciation and amortization 382,000 1,644,000 Selling, general and administrative (including stock-based compensation) 130,000 715,000 Depreciation and amortization 37,000 152,000 Impairment of goodwill - 685,000 Total costs and expenses 549,000 3,196,000 Operating loss (306,000 ) (1,570,000 ) Other income (expense): Interest expense (7,000 ) (21,000 ) Loss on sale of assets held for sale (111,000 ) (111,000 ) Income (loss) before income taxes (424,000 ) (1,702,000 ) Income tax expense (benefit) - - Income (loss) from discontinued operations (424,000 ) (1,702,000 )
Schedule of Assets and Liabilities Held for Sale	Schedule of Assets and Liabilities Held for Sale DSS Digital, Inc. Consolidated Balance Sheets - Assets and Liabilities Held for Sale September 30, 2021 December 31, 2020 unaudited unaudited ASSETS Current assets: Cash $ $ 43,000 Accounts receivable, net - 321,000 Prepaid expenses and other current assets - 167,000 Total current assets - 531,000 Property, plant and equipment, net - 46,000 Total assets - 577,000 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ - $ 25,000 Accrued expenses and deferred revenue - 9,000 Total current liabilities - 34,000 DSS Digital, Inc. Consolidated Statements of Operations - Discontinued Operations (unaudited) 2021 2020 2021 2020 For the Three Months Ended For the Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Revenue: Technology sales, services and licensing $ - $ 483,000 $ 535,000 $ 1,315,000 Total revenue - 483,000 535,000 1,315,000 Costs and expenses: Cost of revenue, exclusive of depreciation and amortization - 70,000 87,000 209,000 Selling, general and administrative (including stock-based compensation) - 226,000 338,000 835,000 Depreciation and amortization - 4,000 5,000 12,000 Total costs and expenses - 300,000 430,000 1,056,000 Operating income - 183,000 105,000 259,000 Income before income taxes - 183,000 105,000 259,000 Income tax expense (benefit) - - - - Income from discontinued operations $ - $ 183,000 $ 105,000 $ 259,000

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	9 Months Ended
	Sep. 30, 2021
Supplemental Cash Flow Elements [Abstract]
Schedule of Supplemental Cash Flow Information	The following table summarizes supplemental cash flows for the nine-months ended September 30, 2021, and 2020: Schedule of Supplemental Cash Flow Information 2021 2020 Cash paid for interest $ 139,000 $ 73,000 Non-cash investing and financing activities: Termination of right of use lease asset $ (744,000 ) $ - Termination of right of use lease liability $ 744,000 $ - Shares received for loan origination fee $ (3,000,000 ) $ - Shares received for prepaid loan interest $ (2,440,000 ) $ - Series A Preferred Shares issued for Impact BioMedical $ - $ 35,187,000 Common Shares issued for Impact Biomedical $ - $ 3,132,000 Long-lived assets acquired through settlement of notes receivable $ - $ 838,000 Acquisition of APB net assets $ 38,765,000 - Shares issued for marketing services $ - $ 210,000

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Schedule of Operations by Reportable Segment	Approximate information concerning the Company’s operations by reportable segment for the three and nine months ended September 30, 2021, and 2020 is as follows. The Company relies on intersegment cooperation and management does not represent that these segments, if operated independently, would report the results contained herein: Schedule of Operations by Reportable Segment Three Months Ended September 30, 2021 Packaging and Printing Investment Banking Direct Marketing Biohealth Group Securities Corporate Total Revenue $ 3,416,000 $ - $ 966,000 $ - $ 184,000 $ - $ 4,566,000 Depreciation and amortization 152,000 - 100,000 278,000 135,000 74,000 739,000 Interest expense 11,000 - - - 37,000 (17,000 ) 31,000 Stock based compensation 1,000 - - - - 12,000 13,000 Net income (loss) from continuing operations 358,000 64,000 (1,304,000 ) (647,000 ) (835,000 ) (4,311,000 ) (6,675,000 ) Capital expenditures 1,399,000 - - - 186,000 55,000 1,640,000 Identifiable assets 24,752,000 60,388,000 43,695,000 55,848,000 11,376,000 23,017,000 219,076,000 Three Months Ended September 30,2020 Packaging and Printing Direct Marketing Biohealth Group Securities Corporate Total Revenue $ 2,971,000 $ 715,000 $ $ $ - $ 3,686,000 Depreciation and amortization 165,000 1,000 - - 78,000 244,000 Interest expense 24,000 - - - 5,000 29,000 Stock based compensation 3,000 - - - 125,000 128,000 Net income (loss) from continuing operations 136,000 (1,139,000 ) - 6,185,000 5,182,000 Capital expenditures 1,000 1,000 - - - 2,000 Identifiable assets 10,013,000 1,809,000 - - 68,305,000 80,127,000 Nine Months Ended September 30, 2021 Packaging and Printing Investment Banking Direct Marketing Biohealth Group Securities Corporate Total Revenue $ 10,652,000 $ - $ 2,382,000 $ - $ 184,000 $ - $ 13,218,000 Depreciation and amortization 459,000 - 419,000 835,000 134,000 228,000 2,075,000 Interest expense 49,000 - 2,000 1,000 87,000 18,000 157,000 Stock based compensation 2,000 - - - - 40,000 42,000 Net income (loss) from continuing operations 641,000 64,000 (9,088,000 ) (1,955,000 ) (1,066,000 ) (10,058,000 ) (21,462,000 ) Capital expenditures 2,621,000 - 6,000 - 6,750,000 4,000 9,381,000 Identifiable assets 24,752,000 60,388,000 43,695,000 55,848,000 11,376,000 23,017,000 219,076,000 Nine Months Ended September 30,2020 Packaging and Printing Direct Marketing Biohealth Group Securities Corporate Total Revenue $ 8,409,000 $ 1,793,000 $ $ $ - $ 10,202,000 Depreciation and amortization 584,000 1,000 - - 227,000 812,000 Interest expense 79,000 - - - 23,000 102,000 Stock based compensation 11,000 - - - 170,000 181,000 Net income (loss) from continuing operations 222,000 (960,000 ) - - 4,249,000 3,511,000 Capital expenditures 91,000 1,000 - - 1,000 93,000 Identifiable assets 10,013,000 1,809,000 - - 68,305,000 80,127,000
Schedule of Disaggregation of Revenue	The following tables disaggregate our business segment revenues by major source: Schedule of Disaggregation of Revenue Printed Products Revenue Information: Three months ended September 30, 2021 Packaging Printing and Fabrication $ 3,373,000 Commercial and Security Printing 43,000 Total Printed Products $ 3,416,000 Three months ended September 30, 2020 Packaging Printing and Fabrication $ 2,568,000 Commercial and Security Printing 403,000 Total Printed Products $ 2,971,000 Nine months ended September 30, 2021 Packaging Printing and Fabrication $ 10,428,000 Commercial and Security Printing 224,000 Total Printed Products $ 10,652,000 Nine months ended September 30, 2020 Packaging Printing and Fabrication $ 7,635,000 Commercial and Security Printing 774,000 Total Printed Products $ 8,409,000 Direct Marketing Three months ended September 30, 2021 Direct Marketing Internet Sales $ 966,000 Total Direct Marketing $ 966,000 Three months ended September 30, 2020 Direct Marketing Internet Sales $ 715,000 Total Direct Marketing $ 715,000 Nine months ended September 30, 2021 Direct Marketing Internet Sales $ 2,382,000 Total Direct Marketing $ 2,382,000 Nine months ended September 30, 2020 Direct Marketing Internet Sales $ 1,793,000 Total Direct Marketing $ 1,793,000 Securities Three months ended September 30, 2021 Rental Income $ 184,000 Total Rental Income $ 184,000 Three months ended September 30, 2020 Rental Income $ - Total Rental Income $ - Nine months ended September 30, 2021 Rental Income $ 184,000 Total Rental Income $ 184,000 Nine months ended September 30, 2020 Rental Income $ - Total Rental Income $ -

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies (Details Narrative) - USD ($)	Sep. 13, 2021	Sep. 09, 2021	May 07, 2021	Aug. 21, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Product Information [Line Items]
Common stock, par value					$ 0.02		$ 0.02
Sale percentage			100.00%
Customer Two [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration Risk, Percentage					43.00%	37.00%
Customer Two [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration Risk, Percentage					73.00%	48.00%
HWH Korea [Member]
Product Information [Line Items]
Shares issued under the term of share exchange					127,179,000
Periodic fee remittance percentage					2.50%
Due from Related Parties					$ 0		$ 1,100,000
Impact BioMedical, Inc. [Member]
Product Information [Line Items]
Shares issued under the term of share exchange				483,334
Common stock, par value				$ 0.02
Shares Issued, Price Per Share				$ 6.48
Impact BioMedical, Inc. [Member] | Series A Preferred Stock [Member]
Product Information [Line Items]
Number of newly issued shares				46,868
Impact BioMedical, Inc. [Member] | Share Exchange Agreement [Member]
Product Information [Line Items]
Shares issued under the term of share exchange				483,334
Common stock, par value				$ 0.02
Shares Issued, Price Per Share				$ 6.48
Impact BioMedical, Inc. [Member] | Share Exchange Agreement [Member] | Series A Preferred Stock [Member]
Product Information [Line Items]
Number of newly issued shares				46,868
American Pacific Bancorp [Member]
Product Information [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned		$ 40,000,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		6,666,700
Business Acquisition, Share Price		$ 6
American Pacific Bancorp [Member] | Common Class A [Member]
Product Information [Line Items]
Common stock, par value		$ 0.01
American Pacific Bancorp [Member] | Stock Purchase Agreement [Member]
Product Information [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned		$ 40,000,200
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		6,666,700
Business Acquisition, Share Price		$ 6
American Pacific Bancorp [Member] | Stock Purchase Agreement [Member] | Common Class A [Member]
Product Information [Line Items]
Common stock, par value		$ 0.01
Liquid Asset Limited Management Limited [Member] | Stock Purchase Agreement [Member]
Product Information [Line Items]
Business Acquisition, Description of Acquired Entity	Under the terms of this agreement, 4000 shares or 40% of the Company’s subsidiary Liquid Asset Limited Management Limited (“LVAM”), a Hong Kong company was transferred to HR1 whereas at the conclusion of the transaction DFMI would own 60% of LVAM and HR1 would own 40%.

Revenue (Details Narrative)

Revenue (Details Narrative) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
Reserve for doubtful accounts	$ 84,000	$ 25,000

Notes Receivable (Details Narra

Notes Receivable (Details Narrative) - USD ($)

May 14, 2021

May 13, 2021

Apr. 05, 2021

Apr. 05, 2021

Feb. 21, 2021

Oct. 10, 2019

Sep. 23, 2021

Sep. 30, 2021

Jun. 30, 2021

Mar. 31, 2021

Sep. 30, 2020

Jun. 30, 2020

Mar. 31, 2020

Sep. 30, 2021

Dec. 31, 2020

Oct. 08, 2021

Sep. 09, 2021

Feb. 08, 2021

Dec. 30, 2020

Debt Instrument, Periodic Payment

$ 537,000

Equity Method Investment, Ownership Percentage

2.00%

Common Stock [Member]

Stock Issued During Period, Shares, New Issues

12,156,000

33,350,000

21,834,000

2,159,000

896,000

863,000

Sharing Service Global Corporation [Member]

Notes receivable

$ 15,043,000

$ 15,043,000

Amortization of Debt Issuance Costs

$ 16,830,000

Sharing Service Global Corporation [Member] | Common Stock [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

150,000,000

150,000,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.22

$ 0.22

Sentinel Brokers Company Inc [Member]

Debt interest rate

6.65%

Convertible Promissory Note [Member]

Outstanding principal and interest

$ 4,156,000

Convertible Promissory Note [Member] | Sentinel Brokers Company Incorporation [Member]

Business Combination, Consideration Transferred

$ 300,000

Convertible Promissory Note [Member] | Sharing Service Global Corporation [Member]

Debt interest rate

8.00%

8.00%

Debt Instrument, Maturity Date

Apr. 5, 2024

Debt instrument conversion price per shares

$ 0.20

$ 0.20

Notes receivable

$ 30,000,000

$ 30,000,000

Loan Processing Fee

3,000,000

Amortized value

$ 83,000

Stock Issued During Period, Shares, New Issues

27,000,000

Convertible Promissory Note [Member] | Sentinel Brokers Company Inc [Member]

Debt Instrument, Maturity Date

May 13, 2023

Notes receivable

$ 600,000

$ 0

0

District Note [Member]

Debt interest rate

4.15%

Debt Instrument, Maturity Date

Sep. 22, 2022

Debt Instrument, Face Amount

$ 3,500,000

Debt Instrument, Redemption, Description

This note may be redeemed prior to maturity with 10 days written notice to APB at a price equal to principal plus interest accrued on the redemption date.

For Loan Origination Fee [Member] | Convertible Promissory Note [Member] | Sharing Service Global Corporation [Member]

Stock Issued During Period, Shares, New Issues

15,000,000

For Prepayment of Interest [Member] | Convertible Promissory Note [Member] | Sharing Service Global Corporation [Member]

Stock Issued During Period, Shares, New Issues

12,000,000

Century TBD Holdings, LLC [Member]

Outstanding principal and interest

$ 500,000

Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger

19.80%

Debt interest rate

6.00%

Debt Instrument, Maturity Date

Oct. 9, 2021

Century TBD Holdings, LLC [Member] | Maximum [Member]

Outstanding principal and interest

$ 500,000

West Park Capital, Inc [Member] | Note and Stock Exchange Agreement [Member]

Equity Method Investment, Ownership Percentage

7.50%

GSX Group Limited [Member] | Convertible Promissory Note [Member]

Outstanding principal and interest

821,000

821,000

$ 800,000

Debt interest rate

4.00%

Debt instrument conversion price per shares

$ 1.05

Dustin Crum [Member] | Convertible Promissory Note [Member]

Outstanding principal and interest

$ 206,000

$ 197,000

$ 197,000

Debt interest rate

6.50%

Debt Instrument, Maturity Date

Aug. 19, 2022

Sentinel Brokers Company Inc [Member]

Equity Method Investment, Ownership Percentage

24.90%

Puradigm LLC [Member] | Secured Convertible Notes [Member]

Debt Instrument, Maturity Date

May 14, 2023

Puradigm LLC [Member] | Convertible Promissory Note [Member]

Outstanding principal and interest

$ 5,000,000

Debt interest rate

6.50%

18.00%

18.00%

Additional Advance Convertable Debt

$ 400,000

Schedule of Cash and Marketable

Schedule of Cash and Marketable Securities by Significant Investment Category (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Cash and Cash Equivalents [Line Items]
Adjusted Cost	$ 91,752,000	$ 11,524,000
Unrealized Gain/(Loss)	(6,522,000)	3,851,000
Fair Value	85,230,000	15,375,000
Cash and Cash Equivalents	69,487,000	5,183,000
Current Marketable Securities	9,207,000	9,136,000
Investments	6,536,000	1,056,000
Fair Value, Inputs, Level 2 [Member] | Warrant [Member]
Cash and Cash Equivalents [Line Items]
Adjusted Cost	15,657,000	700,000
Unrealized Gain/(Loss)	(9,121,000)	356,000
Fair Value	6,536,000	1,056,000
Cash and Cash Equivalents
Current Marketable Securities
Investments	6,536,000	1,056,000
Restricted Cash [Member]
Cash and Cash Equivalents [Line Items]
Adjusted Cost	350,000
Unrealized Gain/(Loss)
Fair Value	350,000
Cash and Cash Equivalents	350,000
Current Marketable Securities
Investments
Cash and Cash Equivalents [Member]
Cash and Cash Equivalents [Line Items]
Adjusted Cost	51,438,000	1,690,000
Unrealized Gain/(Loss)
Fair Value	51,438,000	1,690,000
Cash and Cash Equivalents	51,438,000	1,690,000
Current Marketable Securities
Investments
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Cash and Cash Equivalents [Line Items]
Adjusted Cost	17,699,000	3,493,000
Unrealized Gain/(Loss)
Fair Value	17,699,000	3,493,000
Cash and Cash Equivalents	17,699,000	3,493,000
Current Marketable Securities
Investments
Marketable Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Cash and Cash Equivalents [Line Items]
Adjusted Cost	6,608,000	5,641,000
Unrealized Gain/(Loss)	2,599,000	3,495,000
Fair Value	9,207,000	9,136,000
Cash and Cash Equivalents
Current Marketable Securities	9,207,000	9,136,000
Investments

Schedule of Business Acquisitio

Schedule of Business Acquisition, Pro Forma Information (Details) - American Pacific Bancorp [Member] - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Business Acquisition [Line Items]
Revenue	$ 13,280,000	$ 10,233,000
Net (loss)/income	$ (19,215,000)	$ 1,778,000
Basic (loss)/earnings per share	$ (0.46)	$ 0.63
Diluted (loss)/earnings per share	$ (0.46)	$ 0.46

Acquisitions (Details Narrative

Acquisitions (Details Narrative) - USD ($)	Sep. 09, 2021	Jun. 18, 2021	Aug. 21, 2020	Mar. 03, 2020	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Aug. 18, 2020
Business Acquisition [Line Items]
Ownership percentage	2.00%
Stock issued for acquisition, values					$ 20,301,000
Common Stock, Par or Stated Value Per Share					$ 0.02						$ 0.02		$ 0.02
Stock Issued During Period, Value, New Issues					$ 14,965,000	$ 45,748,000	$ 61,068,000	$ 13,088,000	$ 6,185,000	$ 4,054,000
AMRE Shelton LLC [Member]
Business Acquisition [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired		$ 7,150,000
[custom:InvestmentFacilityAllocated-0]		4,640,000
[custom:RealEstateAllocatedPrice-0]		1,600,000
[custom:LandAndTenantImprovements-0]		325,000
Intangible Assets, Net (Excluding Goodwill)		$ 585,000
Finite-Lived Intangible Asset, Useful Life		3 years
[custom:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesEarnOutDue-0]		$ 1,500,000
IPO [Member]
Business Acquisition [Line Items]
Initial public offering percentage				50.00%
Maximum [Member] | IPO [Member]
Business Acquisition [Line Items]
Shares Issued, Price Per Share				$ 10
AMRE Asset Management Inc. [Member]
Business Acquisition [Line Items]
Ownership percentage				52.50%
American Medical REIT Inc. [Member]
Business Acquisition [Line Items]
Ownership percentage				93.00%
Debt Instrument, Face Amount				$ 800,000	$ 898,000						$ 898,000
Debt Instrument, Maturity Date				Mar. 3, 2022
Debt Instrument, Interest Rate, Stated Percentage				8.00%	8.00%						8.00%
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right				160,000
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 5
Warrants and Rights Outstanding, Maturity Date				Mar. 3, 2024
Shares Issued, Price Per Share		$ 10
Unsecured Debt					$ 200,000						$ 200,000
Number of shares issued on acquisition		264,525
Stock issued for acquisition, values		$ 2,645,250
Acquired percentage		93.00%
Net loss on acquisition					545,000						778,000
Payments to acquire business and non-controlling interest					38,000						131,000
Impact BioMedical, Inc. [Member]
Business Acquisition [Line Items]
Shares Issued, Price Per Share			$ 6.48
Number of shares issued on acquisition			483,334
Common Stock, Par or Stated Value Per Share			$ 0.02
Incurred cost					657,000						1,964,000
Income (Loss) Attributable to Noncontrolling Interest, before Tax					115,000						281,000
Impact BioMedical, Inc. [Member] | Series A Preferred Stock [Member]
Business Acquisition [Line Items]
Ownership percentage														19.99%
Debt Instrument, Interest Rate, Stated Percentage			100.00%
Stock Issued During Period, Shares, New Issues			46,868
Stock Issued During Period, Value, New Issues			$ 46,868,000
Business Combination, Consideration Transferred			50,000,000
Impact BioMedical, Inc. [Member] | Series A Preferred Stock [Member] | Discount For Illiquidity [Member]
Business Acquisition [Line Items]
Stock Issued During Period, Value, New Issues			35,187,000
Business Combination, Consideration Transferred			38,319,000
General and Administrative Expense			$ 295,000
Impact BioMedical, Inc. [Member] | Maximum [Member]
Business Acquisition [Line Items]
Ownership percentage			100.00%
Impact BioMedical, Inc. [Member] | Minimum [Member]
Business Acquisition [Line Items]
Ownership percentage			63.60%
American Pacific Bancorp [Member]
Business Acquisition [Line Items]
Acquired percentage	53.00%
Net loss on acquisition											(19,215,000)	$ 1,778,000
General and Administrative Expense	$ 36,000
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned	$ 40,000,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	6,666,700
Business Acquisition, Share Price	$ 6
Goodwill acquired											16,945,000
Purcahse price of noncontrolling interest											20,301,000
Net assets acquired					3,400,000						3,400,000
Cash					1,250,000						1,250,000
Marketable securities					1,900,000						1,900,000
Notes receivable					330,000						330,000
Accounts payable and accrued liabilities					$ 101,000						$ 101,000
American Pacific Bancorp [Member] | Common Class A [Member]
Business Acquisition [Line Items]
Common Stock, Par or Stated Value Per Share	$ 0.01

Schedule of Operating Result (D

Schedule of Operating Result (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Restructuring Cost and Reserve [Line Items]
Net sales	$ 4,566,000	$ 3,686,000	$ 13,218,000	$ 10,202,000
Operating loss	(5,545,000)	(2,573,000)	(15,991,000)	(4,806,000)
Loss before income taxes	(8,299,000)	5,182,000	(25,777,000)	3,511,000
Income tax benefit	(1,624,000)		(4,315,000)
Net loss	(6,598,000)	$ 5,068,000	$ (18,997,000)	$ 2,376,000
Sharing Service Global Corp [Member]
Restructuring Cost and Reserve [Line Items]
Net sales	11,211,526
Gross profit	7,857,716
Operating loss	(2,021,069)
Loss before income taxes	(2,800,118)
Income tax benefit	747,889
Net loss	$ (3,548,007)

Investments (Details Narrative)

Investments (Details Narrative) - USD ($)	Jul. 22, 2021	May 13, 2021	Apr. 05, 2021	Apr. 02, 2021	Mar. 18, 2021	Mar. 15, 2021	Dec. 19, 2020	Sep. 10, 2020	Aug. 28, 2020	Jul. 22, 2020	Apr. 30, 2021	Jan. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Dec. 31, 2020	Sep. 09, 2021	Jul. 31, 2020
Ownership, percentage																					2.00%
Unrealized Gain (Loss) on Investments																			$ (6,522,000)	$ 3,851,000
Investments													$ 6,536,000						$ 6,536,000	1,056,000
Number of common stock issued, value													$ 14,965,000	$ 45,748,000	$ 61,068,000	$ 13,088,000	$ 6,185,000	$ 4,054,000
Vivacitas Agreement [Member]
Ownership, percentage													19.00%						19.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	1,000,000
Stock Issued During Period, Value, Stock Options Exercised	$ 1,000,000
Chan Heng Fai Ambrose Member]
Unrealized Gain (Loss) on Investments													$ 224,000						$ 732,000
Warrants and Rights Outstanding													$ 324,000						$ 324,000	1,056,000
Chan Heng Fai Ambrose Member] | Common Class A [Member]
Beginning balance, shares										30,000,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right										10,000,000
Warrants and Rights Outstanding										$ 3,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 0.20
Sharing Services Global Corp [Member]
Ownership, percentage																						20.00%
Sharing Services Global Corp [Member] | Common Class A [Member]
Investment Owned, Balance, Shares													91,460,978						91,460,978
Ownership, percentage													46.80%						46.80%
Sharing Service Global Corp [Member]
Ownership, percentage										20.00%
Unrealized Gain (Loss) on Investments													$ 2,780,000	$ 1,645,000					$ 8,745,000
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.22
Acquistion of intangible assets and goodwill										$ 9,192,000
Intangible Assets, Net (Excluding Goodwill)													1,148,000						$ 1,148,000	8,044,000
Finite-Lived Intangible Asset, Useful Life																			5 years
Amortization of Intangible Assets													57,000						$ 287,000
Notes Receivable, Related Parties			$ 30,000,000
Number of warrants issued and vested			150,000,000
[custom:WarrantsExpiration]			Apr. 5, 2026
Fair Value Adjustment of Warrants			$ 14,957,000																6,212,000
Investments													$ 8,688,000						$ 8,688,000
Sharing Service Global Corp [Member] | For Loan Origination Fee [Member]
Beginning balance, shares											15,000,000
Sharing Service Global Corp [Member] | For Prepayment of Interest [Member]
Beginning balance, shares											12,000,000
Sharing Service Global Corp [Member] | Common Class A [Member]
Beginning balance, shares											27,000,000
BMI Capital International LLC [Member].
Ownership, percentage													20.00%		20.00%				20.00%
Impact Oncology PTE Ltd [Member]
Investment Owned, Balance, Shares					2,480,000
Options to purchase additional shares					250,000
Business Combination, Consideration Transferred					$ 2,480,000
Sentinel Brokers Company Inc [Member]
Ownership, percentage		24.90%
Unrealized Gain (Loss) on Investments													$ 11,000						$ 6,000
Investments		$ 750,000											$ 1,050,000						$ 1,050,000
Ownership, percentage		50.10%
Business Combination, Consideration Transferred		$ 300,000
Outstanding Remaining Membership Interest		25.00%
Alset International Limited [Member]
Investment Owned, Balance, Shares													127,179,311						127,179,311
Ownership, percentage													7.00%						7.00%
Marketable Securities													$ 5,990,000						$ 5,990,000	$ 6,830,000
Unrealized Gain (Loss) on Investments													$ 127,000						$ 839,000
DSS Securities, Inc. [Member]
Ownership, percentage								14.90%
Number of common stock issued, value								$ 100,000
Ownership, percentage								10.00%				24.90%
Acquistion description									On or about August 28, 2020, the Company’s wholly owned subsidiary, DSS Securities, Inc. entered into a corporate venture to form and operate a real estate title agency, under the name of Alset Title Company, Inc, a Texas corporation (“ATC”). DSS Securities, Inc. shall own 70% of this venture with the other two shareholders being attorneys necessary to the state application and permitting process. ATC have initiated or have pending applications to do business in a number of states, including Texas, Tennessee, Connecticut, Florida, and Illinois. For the purpose of organization and the state application process, the Company’s CEO, who is a licensed attorney, has a stated non-compensated 15% ownership interest in the venture. There was minimal activity for the three and nine months ended September 30, 2021
BioMed Technologies Asia Pacific Holdings Limited [Member]
Ownership, percentage							4.99%
Beginning balance, shares							525
Number of common stock issued, value							$ 630,000
Vivacitas Oncology Inc [Member]
Beginning balance, shares						500,000
Shares Issued, Price Per Share				$ 1		$ 1
Options to purchase additional shares						1,500,000
Stock Redeemed or Called During Period, Value						$ 500,000
Line of Credit Facility, Periodic Payment, Principal				$ 120,000

Short-Term and Long-Term Debt (

Short-Term and Long-Term Debt (Details Narrative) - USD ($)

Jun. 18, 2021

Mar. 16, 2021

Oct. 31, 2020

Aug. 04, 2020

Jul. 31, 2020

Mar. 02, 2020

Jun. 27, 2019

Sep. 30, 2021

Dec. 31, 2020

Sep. 30, 2020

Sep. 30, 2021

Sep. 30, 2020

Dec. 31, 2020

May 20, 2021

Jun. 30, 2020

Jul. 26, 2017

Line of Credit Facility [Line Items]

Debt Instrument, Periodic Payment

$ 537,000

Gain on extinguishment of debt

$ 116,000

Long term debt, current

498,000

$ 278,000

498,000

278,000

AMRE Shelton LLC [Member]

Line of Credit Facility [Line Items]

Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid

$ 2,829,000

Debt instrument, desription

AMRE Shelton, LLC., (“AMRE Shelton”) a subsidiary of AMRE, entered into a loan agreement (“Shelton Agreement”) with Patriot Bank, N.A. (“Patriot Bank”) in an amount up to $6,155,000, with the amount financed approximating $5,105,000. The Shelton Agreement contains monthly payments of principal and an initial interest 4.25%. The interest will be adjusted commencing on July 1, 2026 and continuing for the next succeeding 5 year period shall be determined one month prior to the change date and shall be an interest rate equal to two hundred fifty (250) basis points above the Federal Home Loan Bank Boston 5-Year/25-Year amortizing advance rate, but in no event less than 4.25% for the term of 120 months

Long term debt, current

$ 191,000

Long term, debt

4,699,000

Deferred financing costs

$ 185,000

Paycheck Protection Program [Member]

Line of Credit Facility [Line Items]

Debt interest rate

1.00%

Debt instrument, face amount

$ 110,000

Debt instrument maturity term

60 months

Debt instrument, desription

The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. These funds were used for payroll, benefits, rent, mortgage interest, and utilities

American Medical REIT Inc. [Member] | Unsecured Promissory Note [Member]

Line of Credit Facility [Line Items]

Debt instrument, maturity date

Mar. 2, 2022

Debt interest rate

8.00%

Debt instrument, face amount

$ 200,000

Warrant exercisable term

4 years

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 5

Unsecured Debt

$ 226,000

$ 226,000

Premier Packaging, DSS Digital, and AAMI [Member]

Line of Credit Facility [Line Items]

Debt instrument, face amount

$ 1,078,000

Debt forgiveness rate

100.00%

100.00%

Gain on extinguishment of debt

969,000

Premier Packaging Bank Of America NA [Member]

Line of Credit Facility [Line Items]

Debt interest rate

2.42%

2.42%

Debt instrument, face amount

$ 1,855,000

$ 1,855,000

Debt Financing Amount

$ 3,200,000

Equipment Line of Credit [Member] | Citizens Bank [Member]

Line of Credit Facility [Line Items]

Line of credit, maximum borrowing amount

$ 900,000

Citizens Bank [Member]

Line of Credit Facility [Line Items]

Line of credit, maximum borrowing amount

$ 800,000

$ 800,000

Debt instrument, maturity date

May 31, 2021

Credit facility, amount outstanding

0

0

Citizens Bank [Member] | Two Promissory Notes [Member]

Line of Credit Facility [Line Items]

Debt instrument, face amount

1,100,000

1,100,000

Citizens Bank [Member] | Premier Packaging Corporation [Member] | Two Promissory Notes [Member]

Line of Credit Facility [Line Items]

Debt instrument, maturity date

Jun. 27, 2029

Debt interest rate

4.22%

Debt instrument, face amount

$ 1,200,000

Debt Instrument, Periodic Payment

7,000

Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid

$ 708,000

Citizens Bank [Member] | Revolving Credit Facility [Member]

Line of Credit Facility [Line Items]

Line of credit, maximum borrowing amount

771,000

771,000

$ 1,200,000

Debt interest rate

2.00%

Citizens Bank [Member] | Equipment Line of Credit [Member]

Line of Credit Facility [Line Items]

Interest rate additional rate above LIBOR

2.00%

Debt instrument, carrying amount

$ 0

$ 0

Citizens Bank [Member] | London Interbank Offered Rate (LIBOR) [Member]

Line of Credit Facility [Line Items]

Interest rate additional rate above LIBOR

2.00%

Citizens Bank [Member] | London Interbank Offered Rate (LIBOR) [Member] | Equipment Line of Credit [Member]

Line of Credit Facility [Line Items]

Interest rate additional rate above LIBOR

2.00%

Debt instrument, maturity date

Jul. 28, 2021

Schedule of Future Minimum Leas

Schedule of Future Minimum Lease Payments (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Lease Liability
2021	$ 59,000
2022	88,000
2023	50,000
2024	4,000
2025	4,000
2026	2,000
Total lease payments	207,000
Less: Imputed Interest	(10,000)
Present value of remaining lease payments	197,000
Current	122,000	$ 167,000
Noncurrent	$ 75,000	$ 15,000
Operating Lease, Weighted Average Remaining Lease Term	10 months 6 days
Weighted-average discount rate	5.40%

Lease Liability (Details Narrat

Lease Liability (Details Narrative)	9 Months Ended
	Sep. 30, 2021
Lease Liability
Lease description	the remaining lease terms on our operating leases range from less than one to five years

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	Mar. 26, 2021	Feb. 15, 2021	Apr. 30, 2019
Maiden Biosciences Inc [Member]
Defined Benefit Plan Disclosure [Line Items]
Loss Contingency, Allegations		Decentralized and HWH, totaling approximately $800,000. Maiden, a 2020 default judgment creditor of RBC, in the principal amount of $4,329,000, now complains about those notes, the funding of those notes, the subsequent default of those notes by RBC, and HWH and Decentralize’s subsequent Article 9 foreclosure or deed-in-lieu debt conveyances. In the instant lawsuit, Maiden asserts claims against Defendants for unjust enrichment, fraudulent transfer under the Texas Uniform Fraudulent Transfer Act, and violation of the Racketeer Influenced and Corrupt Organizations Act. Maiden also seeks a judgment from the court declaring: “(1) Defendants lacked a valid security interest in RBC and RBC Subsidiaries’ assets and therefore lacked the authority to sell the assets during the public foreclosure sale; (2) Defendant Heuszel’s low bid at the public foreclosure sale was invalid and void; (3) the public foreclosure sale was conducted in a commercially unreasonable manner; and (4) Defendants do not have the legal authority to transfer RBC and RBC’s Subsidiaries assets to Heuszel and HWH.” Maiden seeks to recover from Defendants: (1) treble damages or, alternatively, damages in the amount of their underlying judgment plus the other creditors’ claims or the value of the assets transferred, whichever is less, plus punitive or exemplary damages; (2) pre and post-judgment interest; and (3) attorneys’ fees and cost
Jeffrey Ronaldi [Member]
Defined Benefit Plan Disclosure [Line Items]
Loss Contingency, Allegations			In April 2019 DSS commenced an action in New York State Supreme Court, Monroe County, Index No. E2019003542, against Jeffrey Ronaldi, our former Chief Executive Officer. This New York action seeks a declaratory judgment that, contrary to informal claims made by him, Mr. Ronaldi’s employment agreement with us expired by its terms and that he is not entitled to any cash bonuses or other unpaid amounts. The lawsuit also seeks an injunction against Mr. Ronaldi from interfering with any of DSS’ IP litigation. Mr. Ronaldi subsequently commenced an action against DSS in the Superior Court of California, County of San Diego, on November 8, 2019, under case number 37-2019-00059664-CU-CO-CTL, in which he alleged that DSS terminated his employment in April 2019 in order to avoid paying him certain employment-related amounts. DSS was successful in dismissing the California case and consolidating it with the action pending in Monroe County, New York. Mr. Ronaldi asserted counterclaims in the Monroe County, New York action similar to those he originally brought in California. Mr. Ronaldi claims that his termination violated an alleged employment agreement or implied-in-fact employment agreement and that he should have remained employed through 2019. Mr. Ronaldi seeks to recover: (i) $144,658 in wages from April 11, 2019 through December 31, 2019; (ii) $769 in alleged unpaid based salary for time worked before April 11, 2019; (iii) $15,385 in alleged paid time off compensation; (iv) $3,077 in alleged unpaid sick time compensation; (v) $26,077 in waiting-time penalties; (vi) $91,000 in unspecified expense reimbursement; (vii) $300,000 in alleged cash bonuses ($100,000 per year) based on DSS’s performance in 2017, 2018 and 2019; and (viii) a $450,000 performance bonus based on the result of certain alleged net proceeds from patent infringement litigation. He further claims an interest in any recovery in DSS Technology Management v. Apple, Inc., Case No. 4:14-cf05330-HSG. The parties are now engaged in discovery
Legal Fees	$ 160,896

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)

Sep. 03, 2021

Jun. 21, 2021

May 28, 2021

May 26, 2021

Feb. 04, 2021

Jan. 19, 2021

Oct. 16, 2020

Aug. 21, 2020

Aug. 18, 2020

Jun. 04, 2020

Sep. 30, 2021

Jun. 30, 2021

Mar. 31, 2021

Sep. 30, 2020

Jun. 30, 2020

Mar. 31, 2020

Sep. 30, 2021

Sep. 30, 2020

Sep. 09, 2021

Dec. 31, 2020

Class of Stock [Line Items]

Preferred stock shares desginated

47,000

Preferred stock liquidation per share

$ 1,000

Preferred stock liquidation value

$ 43,000,000

Equity Method Investment, Ownership Percentage

2.00%

Common stock, par value

$ 0.02

$ 0.02

$ 0.02

Investments

$ 6,536,000

$ 6,536,000

$ 1,056,000

Share-based Payment Arrangement, Expense

$ 13,000

$ 42,000

Earnings Per Share, Basic and Diluted

$ 0.01

$ 0.01

Share based compensation

$ 74,000

$ 181,000

Investor Relations Firm [Member]

Class of Stock [Line Items]

Number of common stock shares issues

21,000

Stock Issued During Period, Value, New Issues

$ 210,000

Share based compensation

$ 15,000

$ 105,000

A E I Subscription Agreement [Member]

Class of Stock [Line Items]

Common stock, par value

$ 0.02

Purchase price per share

$ 1.234

Investments

$ 15,000,000

Exchange of shares

12,156,000

Common Stock [Member]

Class of Stock [Line Items]

Beginning balance, shares

12,156,000

33,350,000

21,834,000

2,159,000

896,000

863,000

Series A Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock liquidation value

$ 1,000

Impact BioMedical, Inc. [Member]

Class of Stock [Line Items]

Number of authorized shares of preferred stock

47,000

Preferred stock par value

$ 0.02

Common stock, par value

$ 0.02

Purchase price per share

$ 6.48

Impact BioMedical, Inc. [Member] | Maximum [Member]

Class of Stock [Line Items]

Equity Method Investment, Ownership Percentage

100.00%

Impact BioMedical, Inc. [Member] | Series A Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock shares desginated

47,000

Preferred stock liquidation per share

$ 1,000

Preferred stock liquidation value

$ 46,868,000

Conversion price

$ 6.48

Conversion shares

154.32

Equity Method Investment, Ownership Percentage

19.99%

Beginning balance, shares

46,868

Impact BioMedical, Inc. [Member] | Series A Preferred Stock [Member] | Common Stock [Member]

Class of Stock [Line Items]

Conversion shares

7,232,670

Global BioMedical Pte Ltd [Member] | Series A Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Conversion shares

7,259

35,316

4,293

Global BioMedical Pte Ltd [Member] | Common Class A [Member]

Class of Stock [Line Items]

Conversion shares

1,120,170

5,450,000

662,500

Aegis Capital Corp [Member] | Jan. 2021 Underwriting Agreement [Member]

Class of Stock [Line Items]

Beginning balance, shares

6,666,666

Common stock, par value

$ 0.02

Purchase price per share

$ 3.60

Proceeds from net offering

$ 24,900,000

Aegis Capital Corp [Member] | Jan. 2021 Underwriting Agreement [Member] | Maximum [Member]

Class of Stock [Line Items]

Options to purchase additional shares

1,000,000

Aegis Capital Corp [Member] | Feb. 2021 Underwriting Agreement [Member]

Class of Stock [Line Items]

Beginning balance, shares

12,319,346

Common stock, par value

$ 0.02

Purchase price per share

$ 2.80

Proceeds from net offering

$ 36,140,000

Aegis Capital Corp [Member] | Feb. 2021 Underwriting Agreement [Member] | Maximum [Member]

Class of Stock [Line Items]

Options to purchase additional shares

1,847,901

Aegis Capital Corp [Member] | May. 2021 Underwriting Agreement [Member]

Class of Stock [Line Items]

Beginning balance, shares

29,000,000

Common stock, par value

$ 0.02

Purchase price per share

$ 1.50

Proceeds from net offering

$ 45,750,000

Aegis Capital Corp [Member] | May. 2021 Underwriting Agreement [Member] | Maximum [Member]

Class of Stock [Line Items]

Options to purchase additional shares

4,350,000

Schedule of Discontinued Operat

Schedule of Discontinued Operations (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Total revenue	$ 4,566,000	$ 3,686,000	$ 13,218,000	$ 10,202,000
Cost of revenue, exclusive of depreciation and amortization	3,184,000	2,566,000	9,513,000	6,869,000
Selling, general and administrative (including stock-based compensation)	6,188,000	3,449,000	17,621,000	7,327,000
Depreciation and amortization	739,000	244,000	2,075,000	812,000
Total costs and expenses	10,111,000	6,259,000	29,209,000	15,008,000
Operating loss	(5,545,000)	(2,573,000)	(15,991,000)	(4,806,000)
Income (loss) before income taxes	(8,299,000)	5,182,000	(25,777,000)	3,511,000
Income tax expense (benefit)	1,624,000		4,315,000
Income (loss) from discontinued operations		(240,000)	2,129,000	(1,442,000)
Plastic Printing Professionals, Inc [Member]
Income (loss) from discontinued operations			390,000
Discontinued Operations [Member] | Plastic Printing Professionals, Inc [Member]
Total revenue		243,000		1,626,000
Cost of revenue, exclusive of depreciation and amortization		382,000		1,644,000
Selling, general and administrative (including stock-based compensation)		130,000		715,000
Depreciation and amortization		37,000		152,000
Impairment of goodwill				685,000
Total costs and expenses		549,000		3,196,000
Operating loss		(306,000)		(1,570,000)
Interest expense		(7,000)		(21,000)
Loss on sale of assets held for sale		(111,000)		(111,000)
Income (loss) before income taxes		(424,000)		(1,702,000)
Income tax expense (benefit)
Income (loss) from discontinued operations		(424,000)		(1,702,000)
Printed Products [Member]
Total revenue	$ 3,416,000	2,971,000	$ 10,652,000	8,409,000
Printed Products [Member] | Discontinued Operations [Member] | Plastic Printing Professionals, Inc [Member]
Total revenue		$ 243,000		$ 1,626,000

Schedule of Assets and Liabilit

Schedule of Assets and Liabilities Held for Sale (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash	$ 69,137,000		$ 69,137,000		$ 5,183,000
Accounts receivable, net	2,774,000		2,774,000		3,589,000
Prepaid expenses and other current assets	1,469,000		1,469,000		1,192,000
Total current assets	96,981,000		96,981,000		12,450,000
Property, plant and equipment, net	6,396,000		6,396,000		4,100,000
Total assets	219,076,000		219,076,000		91,919,000
Accounts payable	1,948,000		1,948,000		1,457,000
Accrued expenses and deferred revenue	9,555,000		9,555,000		5,260,000
Total current liabilities	12,538,000		12,538,000		8,872,000
Total revenue	4,566,000	$ 3,686,000	13,218,000	$ 10,202,000
Cost of revenue, exclusive of depreciation and amortization	3,184,000	2,566,000	9,513,000	6,869,000
Selling, general and administrative (including stock-based compensation)	6,188,000	3,449,000	17,621,000	7,327,000
Depreciation and amortization	739,000	244,000	2,075,000	812,000
Total costs and expenses	10,111,000	6,259,000	29,209,000	15,008,000
Operating loss	(5,545,000)	(2,573,000)	(15,991,000)	(4,806,000)
(Loss) income from continuing operations before income taxes	(8,299,000)	5,182,000	(25,777,000)	3,511,000
Income tax expense (benefit)	1,624,000		4,315,000
Income from discontinued operations		(240,000)	2,129,000	(1,442,000)
DSS Digital Inc [Member] | Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total revenue		483,000	535,000	1,315,000
Cost of revenue, exclusive of depreciation and amortization		70,000	87,000	209,000
Selling, general and administrative (including stock-based compensation)		226,000	338,000	835,000
Depreciation and amortization		4,000	5,000	12,000
Total costs and expenses		300,000	430,000	1,056,000
Operating loss		183,000	105,000	259,000
(Loss) income from continuing operations before income taxes		183,000	105,000	259,000
Income tax expense (benefit)
Income from discontinued operations		183,000	105,000	259,000
DSS Digital Inc [Member] | Technology Sales, Services and Licensing [Member] | Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total revenue		$ 483,000	535,000	$ 1,315,000
Discontinued Operations, Held-for-sale [Member] | DSS Digital Inc [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash					43,000
Accounts receivable, net					321,000
Prepaid expenses and other current assets					167,000
Total current assets					531,000
Property, plant and equipment, net					46,000
Total assets					577,000
Accounts payable					25,000
Accrued expenses and deferred revenue					9,000
Total current liabilities					$ 34,000

Discontinued Operations (Detail

Discontinued Operations (Details Narrative) - USD ($)	May 07, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 09, 2021	Dec. 31, 2020
Income (loss) from discontinued operations, net of tax			$ (240,000)	$ 2,129,000	$ (1,442,000)
Equity Method Investment, Ownership Percentage						2.00%
Purchase Agreement [Member]
Equity Method Investment, Ownership Percentage	100.00%
Debt Securities, Available-for-sale, Purchased with Credit Deterioration, Amount at Purchase Price	$ 5,000,000
Cash	3,000,000
Potential earnout	1,500,000
Trade credit, not yet utilized	$ 500,000
Long-term Line of Credit		500,000		500,000
Plastic Printing Professionals, Inc [Member]
Consideration paid to sale of assets				683,000
Income (loss) from discontinued operations, net of tax				390,000
Gain (Loss) on Disposition of Property Plant Equipment			$ 111,000
Discontinued operation asset, non current							$ 744,000
Liabilities of disposal group including discontinued operations, current							240,000
Liabilities of disposal group including discontinued operations, non-current							$ 505,000
Costs incurred on wind down activities				204,000
Plastic Printing Professionals, Inc [Member] | Based on Future Quarterly Gross Revenue [Member]
Cash Investment Net				$ 517,000
DSS Digital Inc [Member]
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax		$ 2,226,000

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Effective Income Tax Rate Reconciliation, Percent	1730.00%
Discrete tax expense	$ 83,000
Discontinued Operation, Tax Effect of Discontinued Operation	596,000
Net operating loss carryforwards		$ 56,700,000
Expected realized amount, deferred tax assets		2,100,000
Unrecognized tax benefits	$ 0	$ 0

Schedule of Supplemental Cash F

Schedule of Supplemental Cash Flow Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Supplemental Cash Flow Elements [Abstract]
Cash paid for interest	$ 139,000	$ 73,000
Termination of right of use lease asset	(744,000)
Termination of right of use lease liability	744,000
Shares received for loan origination fee	(3,000,000)
Shares received for prepaid loan interest	(2,440,000)
Series A Preferred Shares issued for Impact BioMedical		35,187,000
Common Shares issued for Impact Biomedical		3,132,000
Long-lived assets acquired through settlement of notes receivable		838,000
Acquisition of APB net assets	38,765,000
Shares issued for marketing services		$ 210,000

Schedule of Operations by Repor

Schedule of Operations by Reportable Segment (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Segment Reporting Information [Line Items]
Total revenue	$ 4,566,000	$ 3,686,000	$ 13,218,000	$ 10,202,000
Total revenue	739,000	244,000	2,075,000	812,000
Total revenue	31,000	29,000	157,000	102,000
Total revenue	13,000	128,000	42,000	181,000
Total revenue	(6,675,000)	5,182,000	(21,462,000)	3,511,000
Total revenue	1,640,000	2,000	9,381,000	93,000
Total revenue	219,076,000	80,127,000	219,076,000	80,127,000
Operating Segments [Member] | Premier Packaging [Member]
Segment Reporting Information [Line Items]
Total revenue	3,416,000	2,971,000	10,652,000	8,409,000
Total revenue	152,000	165,000	459,000	584,000
Total revenue	11,000	24,000	49,000	79,000
Total revenue	1,000	3,000	2,000	11,000
Total revenue	358,000	136,000	641,000	222,000
Total revenue	1,399,000	1,000	2,621,000	91,000
Total revenue	24,752,000	10,013,000	24,752,000	10,013,000
Operating Segments [Member] | Investment Banking [Member]
Segment Reporting Information [Line Items]
Total revenue
Total revenue
Total revenue
Total revenue
Total revenue	64,000		64,000
Total revenue
Total revenue	60,388,000		60,388,000
Operating Segments [Member] | Direct Marketing/Online Sales [Member]
Segment Reporting Information [Line Items]
Total revenue	966,000	715,000	2,382,000	1,793,000
Total revenue	100,000	1,000	419,000	1,000
Total revenue			2,000
Total revenue
Total revenue	(1,304,000)	(1,139,000)	(9,088,000)	(960,000)
Total revenue		1,000	6,000	1,000
Total revenue	43,695,000	1,809,000	43,695,000	1,809,000
Operating Segments [Member] | Biohealth [Member]
Segment Reporting Information [Line Items]
Total revenue
Total revenue	278,000		835,000
Total revenue			1,000
Total revenue
Total revenue	(647,000)		(1,955,000)
Total revenue
Total revenue	55,848,000		55,848,000
Operating Segments [Member] | Securities [Member]
Segment Reporting Information [Line Items]
Total revenue	184,000		184,000
Total revenue	135,000		134,000
Total revenue	37,000		87,000
Total revenue
Total revenue	(835,000)		(1,066,000)
Total revenue	186,000		6,750,000
Total revenue	11,376,000		11,376,000
Operating Segments [Member] | Corporate Segment [Member]
Segment Reporting Information [Line Items]
Total revenue
Total revenue	74,000	78,000	228,000	227,000
Total revenue	(17,000)	5,000	18,000	23,000
Total revenue	12,000	125,000	40,000	170,000
Total revenue	(4,311,000)	6,185,000	(10,058,000)	4,249,000
Total revenue	55,000		4,000	1,000
Total revenue	$ 23,017,000	$ 68,305,000	$ 23,017,000	$ 68,305,000

Schedule of Disaggregation of R

Schedule of Disaggregation of Revenue (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Segment Reporting Information [Line Items]
Total Printed Products	$ 3,416,000	$ 2,971,000	$ 10,652,000	$ 8,409,000
Direct Marketing	966,000	715,000	2,382,000	1,793,000
Total Rental Income	184,000		184,000
Packaging Printing and Fabrication [Member]
Segment Reporting Information [Line Items]
Total Printed Products	3,373,000	2,568,000	10,428,000	7,635,000
Commercial and Security Printing [Member]
Segment Reporting Information [Line Items]
Total Printed Products	43,000	403,000	224,000	774,000
Direct Marketing Internet Sales [Member]
Segment Reporting Information [Line Items]
Direct Marketing	966,000	715,000	2,382,000	1,793,000
Securities [Member]
Segment Reporting Information [Line Items]
Total Rental Income	$ 184,000		$ 184,000

Segment Information (Details Na

Segment Information (Details Narrative)	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Number of operating segments	five

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	Oct. 13, 2021USD ($)	Nov. 04, 2021USD ($)ft²$ / shares	Sep. 30, 2021
Subsequent Event [Line Items]
Lessee, Operating Lease, Description			the remaining lease terms on our operating leases range from less than one to five years
Subsequent Event [Member] | American Pacific Bancorp [Member]
Subsequent Event [Line Items]
Convertible Notes Payable		$ 13,940,000
Subsequent Event [Member] | Alset International Limited [Member]
Subsequent Event [Line Items]
Convertible Notes Payable		8,350,000
Subsequent Event [Member] | AMRE [Member]
Subsequent Event [Line Items]
Acquisition purchase price		$ 62,000,000
Lessee, Operating Lease, Description		The medical facilities acquired by AMRE are currently under an 18-year lease with eleven years remaining and an option to renew for an additional five years.
Lessee, Operating Lease, Renewal Term		18 years
Lessee, Operating Lease, Remaining Lease Term		11 years
Area of Land | ft²		320,000
Debt interest rate		8.00%
Debt payment terms, description		payable in cash quarterly in arrears commencing on the 29th day of January 2022, and continue on the 29th day of each April, July, October and January thereafter through maturity
Debt conversion description		At the option of the Company, the unpaid principal and interest balance on the note may be converted, in whole or in part, at any time on or before the maturity date, into fully-paid and non-assessable shares of common stock par value $0.001 per share of common stock of AMRE at a conversion rate equal to $10.00 per share
Debt Instrument, Convertible, Conversion Price | $ / shares		$ 10
Debt maturity date description		These facilities have varying maturity dates through November 2023
Subsequent Event [Member] | Loan Agreement [Member]
Subsequent Event [Line Items]
Debt Instrument, Maturity Date	Oct. 12, 2022
Subsequent Event [Member] | Loan Agreement [Member] | Maximum [Member]
Subsequent Event [Line Items]
Loans Receivable, Fair Value Disclosure	$ 3,000,000